| x | ANNUAL      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|---|------------------------------------------------------------------------------------------------|

| ¨ | TRANSITION      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|--------|----------------------------------------------------------------------------------------------------|

|                                                            |
|------------------------------------------------------------|
| (Exact      Name of Registrant as Specified in ItsCharter) |

|   | Delaware                                      |   | 22-2322400                                |   |
|--------|-----------------------------------------------|--------|-------------------------------------------|--------|
|   | (State      or Other Jurisdiction of          |   | (I.R.S.      Employer Identification No.) |   |
|   | Incorporation      or Organization)           |   |                                      |   |
|   |                                          |   |                                      |   |
|   | 650      College Road East, Suite 3100        |   |                                      |   |
|   | Princeton,      New Jersey                    |   | 08540                                     |   |
|   |                                          |   |                                      |   |
|   | (Address      of Principal Executive Offices) |   | (Zip      Code)                           |   |

| Registrant's      telephone number, including area code: | (609)      750-8200 |
|----------------------------------------------------------|---------------------|

|   | Securities      registered pursuant to Section 12(b) of theAct: |
|--------|-----------------------------------------------------------------|

|  Title      of Each Class               |   | Name      of Each Exchange onwhich      Registered |
|----------------------------------------------|--------|----------------------------------------------------|
| Common      Stock, $0.01 par value per share |   | The      NASDAQ                                    |
|                                         |   | Stock      Market LLC                              |

|   | Securities      registered pursuant to Section 12(g) of theAct: |
|--------|-----------------------------------------------------------------|

|   |     Preferred Stock      Purchase Rights, $0.01 par value pershare |
|--------|----------------------------------------------------------------------------------------|

----

Table of Contents

| Large      Accelerated Filer ¨ | Accelerated      Filer ¨ | Non-      Accelerated Filer ¨ | Smaller      Reporting Company x |
|-------------------------------------|------------------------------------|-----------------------------------------|----------------------------------|

----

Table of Contents

TABLE OF CONTENTS

|     | Item   |                                                                                                                | Page   |
|----------|--------|---------------------------------------------------------------------------------------------------------------------|--------|
|     |   |                                                                                                                |   |
| PART I   | 1.     | Business                                                                                                            | 3      |
|     |   |                                                                                                                |   |
|     | 1A.    | Risk Factors                                                                                                        | 37     |
|     |   |                                                                                                                |   |
|     | 1B.    | Unresolved Staff Comments                                                                                           | 63     |
|     |   |                                                                                                                |   |
|     | 2.     | Properties                                                                                                          | 64     |
|     |   |                                                                                                                |   |
|     | 3.     | Legal Proceedings                                                                                                   | 64     |
|     |   |                                                                                                                |   |
|     | 4.     | Submission of Matters to a Vote of Security      Holders                                                            | 64     |
|     |   |                                                                                                                |   |
| PART II  | 5.     | Market for the Company's Common Equity, Related Stockholder      Matters and Company Purchases of Equity Securities | 65     |
|     |   |                                                                                                                |   |
|     | 6.     | Selected Financial Data                                                                                             | 67     |
|     |   |                                                                                                                |   |
|     | 7.     | Management's Discussion and Analysis of Financial Condition and      Results of Operations                          | 68     |
|     |   |                                                                                                                |   |
|     | 7A.    | Quantitative and Qualitative Disclosures About Market      Risk                                                     | 91     |
|     |   |                                                                                                                |   |
|     | 8.     | Financial Statements and Supplementary Data                                                                         | 91     |
|     |   |                                                                                                                |   |
|     | 9.     | Changes in and Disagreements with Accountants on Accounting and      Financial Disclosure                           | 92     |
|     |   |                                                                                                                |   |
|     | 9A.    | Controls and Procedures                                                                                             | 92     |
|     |   |                                                                                                                |   |
|     | 9B.    | Other Information                                                                                                   | 96     |
|     |   |                                                                                                                |   |
| PART III | 10.    | Directors, Executive Officers and Corporate      Governance                                                         | 96     |
|     |   |                                                                                                                |   |
|     | 11.    | Executive Compensation                                                                                              | 96     |
|     |   |                                                                                                                |   |
|     | 12.    | Security Ownership of Certain Beneficial Owners and Management      and Related Stockholder Matters                 | 96     |
|     |   |                                                                                                                |   |
|     | 13.    | Certain Relationships and Related Transactions, and Director      Independence                                      | 96     |
|     |   |                                                                                                                |   |
|     | 14.    | Principal Accountant Fees and Services                                                                              | 97     |

----

Table of Contents

|                                       |   |                                          |   |
|--------------------------------------------|--------|-----------------------------------------------|--------|
| PART IV                                    | 15.    | Exhibits and Financial Statement    Schedules | 97     |
|                                       |   |                                          |   |
| SIGNATURES                                 | 108    |
|                                       |   |                                          |   |
| INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | F-1    |

----

Table of Contents

----

Table of Contents

----

Table of Contents

PART I

| Item 1. | Business |
|---------|----------|

Overview

|   | · | Expanding our near- and      long-term revenues. We have implemented an in-licensing program to      broaden our revenue base with product opportunities that are complementary      to our commercial presence in oncology.  In October 2006, we      acquired the commercial rights to CAPHOSOL from InPharma A/S, or      InPharma. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | · | Maximizing the market      potential of our approved products through data-driven      initiatives.  A  data-driven strategy is      underway to enhance the market opportunities for our products within their      currently approved indications.  During 2007 we launched a      multi-site patient registry designed to evaluate the use of CAPHOSOL in      patients with a variety of cancers receiving treatments that put them at      risk for development of oral mucositis. We are supporting post-marketing      studies for QUADRAMET to optimize its potential as a safe, effective,      non-narcotic option for the palliation of pain from cancers that have      spread to the bone.  We are also advancing initiatives to      position PROSTASCINT as an important tool for managing the care of      prostate cancer.  Recent progress includes:  (i) the      publication of new data in the American Cancer Society's peer-reviewed      journal, Cancer,      demonstrating repeated dosing of QUADRAMET to be a safe and effective      treatment option for patients with recurrent painful bone metastases; (ii)      the expanded inclusion of PROSTASCINT within the National Comprehensive      Cancer Network's, or NCCN clinical practice guidelines to include patients      with recurrent disease; and (iii) the publication of seven-year survival      data in the American Brachytherapy Society's peer-reviewed journal, Brachytherapy,      demonstrating the potential for PROSTASCINT fusion imaging to help      determine patient-specific treatment regimens for prostate cancer patients      undergoing brachytherapy. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Building long-term      sustainability.  We are focused on maintaining a balanced      specialty portfolio through three key imperatives:  (i)      evaluating new indications for our marketed products; (ii) accessing      product candidates complementary to our commercial presence; and (iii)      monetizing assets that are no longer a strategic fit and realigning our      investment on projects that are in line with our business      objectives.  Our 2007 progress includes the presentation of data      for QUADRAMET in combination with bortezomib for relapsed multiple      myeloma, presentation of Phase 1 data for QUADRAMET in combination with      docetaxel for patients with castrate metastatic prostate cancer and      presentation of QUADRAMET in combination with radiation and chemotherapy      for patients with osteosarcoma. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|   | · | Distinguishing the physical      properties of QUADRAMET from earlier generation agents within its      class.  We believe the limited use of QUADRAMET for the      palliation of disseminated painful bone metastases has evolved due to the      myelosuppression associated with earlier generation radiopharmaceuticals,      such as strontium-89.  While to date, there are no head-to-head      clinical trials comparing QUADRAMET and strontium-89, we believe, there      are several key differentiating features that distinguish QUADRAMET from      strontium-89.  First, QUADRAMET's physical half life is 1.9      days, as compared to 50.5 days for strontium-89.  A shorter half      life results in a much faster time to deliver the total dose of radiation,      as well as a shorter exposure to radioactivity.  In addition,      particle emissions from strontium-89 are significantly higher in energy      compared to QUADRAMET, and higher-energy particles are associated with      larger volumes of marrow exposed to radiation.  These key      differences have been highlighted in recent peer-reviewed publications      that our field force can utilize when they present QUADRAMET to health      care providers. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Empowering and marketing to      key prescribing audiences.  We have broadened our      commercial focus and are now introducing QUADRAMET to both medical and      radiation oncologists, as we believe the effective treatment of bone      metastases requires a cooperative effort between the two      specialties.  We have retrained and refocused our sales force      with new resources that highlight QUADRAMET's attributes for treating      painful bone metastases, such as its rapid onset and duration of      relief. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | · | Generating data to support the      role of QUADRAMET in contemporary oncology settings with other commonly      used cancer therapeutics.  We are supporting various      clinical development initiatives evaluating QUADRAMET in combination with      chemotherapies and biologics for prostate cancer, multiple myeloma, and      osteosarcoma.  These trials are designed with two key      objectives.  First, to broaden QUADRAMET's market potential      within its currently approved treatment setting for pain palliation by      evaluating the safety and tolerability of administering QUADRAMET in      combination with other cancer regimens.  Second, to support our      longer-term strategy for maximizing the QUADRAMET brand by progressing      QUADRAMET beyond its currently approved treatment setting as a potential      therapeutic for cancer that has spread to the bone as discussed      below. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|   | · | Positioning PROSTASCINT fusion      imaging as the standard of care for prostate cancer      imaging.  PROSTASCINT fusion imaging combines anatomic      and functional information to provide a complete pathology picture in a      single exam.  This can help physicians eliminate guesswork and      enable them to better plan and individualize patient      treatment.  PROSTASCINT fusion imaging can be accomplished      through software or hardware solutions.  Of the approximately      400 sites able to perform PROSTASCINT imaging, there are approximately 200      sites currently proficient in PROSTASCINT fusion imaging.  We      are focusing our promotional efforts in hospitals and clinics that are      already utilizing fusion technology and are skilled in the performance of      PROSTASCINT scans.  We believe that by focusing promotional      activity in and around these sites that already appreciate the prognostic      value of PROSTASCINT, we can increase the number of prostate cancer      patients being referred in a very cost effective  manner. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Generating awareness of the      prognostic value of the PSMA antigen.  There is a growing      body of clinical data demonstrating that over-expression of PSMA in      prostate cancer patients correlates with other adverse prognostic factors      and can independently predict disease recurrence.  We are      focused on generating awareness of PSMA as an important prognostic marker      for prostate cancer and positioning PROSTASCINT as an important tool for      identifying patients who may benefit from more intensive treatment      regimens. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Leveraging the presentation      and publication of outcomes data.  In 2007, outcomes data      from recent and ongoing clinical trials of PROSTASCINT were reported at      major medical meetings and in the peer-reviewed publications, Brachytherapy and      Urology.  These data continue to support the potential of      PROSTASCINT fusion imaging      as an important tool to define patients with local or metastatic disease,      help clarify treatment decisions, and prevent or limit treatment-related      side effects.  |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | · | Advancing image-guided therapy      applications.  The advances in nuclear medicine imaging      SPECT equipment, computer workstation power, as well as software      enhancements allow researchers to utilize cutting-edge imaging technology      to explore novel applications of the enhanced PROSTASCINT      image.  With fusion of an enhanced SPECT, the PROSTASCINT image      is registered with CT and/or MR anatomic images; the resulting images have      been applied to clinical research in areas of guided brachytherapy (or      radioactive seeds), guided external beam radiation therapy (EBRT),      intensity modulated radiation therapy (IMRT), and image-guided      biopsy.  The potential of this application is described in the      previously discussed 2007 publication reporting seven-year biochemical      outcomes after image-guided brachytherapy using PROSTASCINT fusion      imaging.  The publication, "Biochemical disease free survival      rates following definitive low dose rate prostate brachytherapy with dose      escalation to biologic target volumes identified with SPECT/CT Capromab      Pendetide," by Ellis et al. appeared in the American Brachytherapy      Society's peer-reviewed journal, Brachytherapy      (Brachytherapy Volume 6, Issue 1, January-March 2007, Pages      16-25.) |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|   | · | Discovering      novel signal transduction pathways and their relevant protein-protein      interactions, such as rapidly identifying qualified drug targets and      identifying potential unwanted sideeffects. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Identifying      structure and activity relationship (SAR) information regarding domain and      ligand interactions that can facilitate small molecule drug      design. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Providing      high throughput screening reagents (e.g., cloned domains and      ligands). |
|--------|--------|--------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|   | · | Additional      patents will be issued to us in any or all appropriate      jurisdictions. |
|--------|--------|--------------------------------------------------------------------------------------------|

|   | · | Litigation      will not be commenced seeking to challenge our patent protection or that      challenges will not be successful. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------|

|   | · | Our      processes or products do not or will not infringe upon the patents of      third parties. |
|--------|--------|----------------------------------------------------------------------------------------------------|

|   | · | The      scope of patents issued will successfully prevent third parties from      developing similar and competitiveproducts. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|   | · | Preclinical      laboratory and animal tests that are conducted consistent with the FDA's      good laboratory practiceregulations. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Submission      to the FDA of an Investigational New Drug Application (IND) (for a drug or      biologic) or Investigational Device Exemption (IDE) (for a device), which      must become effective before clinical trials may begin; further, approval      of the investigation by an Institutional Review Board (IRB) must also be      obtained before the investigational product may be given to human      subjects. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Human      clinical trial(s) to establish the safety and efficacy of the product for      its intended indication. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------|

|   | · | Submission      to the FDA of a marketing application-New Drug Application (NDA) for a      drug, Biologics License Application (BLA) for a biologic, and a premarket      approval application (PMA) or premarket notification (510(k)) for a      device. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | FDA      review and approval or clearance of the marketing      application.  Radiopharmaceutical drugs are subject to      additional requirements pertaining to the description and support of their      indications for use, and the evaluation of product effectiveness and      safety, including, radiation safety.  We cannot assure you that      the FDA review of marketing applications will result in product approval      or clearance on a timely basis, or atall. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item      1A. | Risk      Factors |
|---------------|-------------------|

Investing

----

Table of Contents

----

Table of Contents

|   | Ÿ | undergoing      steps to realign and implement our focus as a product-driven      biopharmaceutical company; |
|--------|--------|--------------------------------------------------------------------------------------------------------------|

|   | Ÿ | establishing      and maintaining our in-house specialty sales force;  and |
|--------|--------|----------------------------------------------------------------------------|

|   | Ÿ | enhancing      our marketed product portfolio through marketing alliances and strategic      arrangements. |
|--------|--------|------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|   | Ÿ | health      care providers, such as hospitals and physicians;  and |
|--------|--------|--------------------------------------------------------------------|

|   | Ÿ | third-party      payors, including Medicare, Medicaid, private insurance carriers and      health maintenance organizations. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|   | · | a      license agreement with The Dow Chemical Company relating to the QUADRAMET      technology; |
|--------|--------|---------------------------------------------------------------------------------------------------|

|   | · | a      manufacturing and supply agreement for the manufacture of QUADRAMET with      BMSMI; |
|--------|--------|---------------------------------------------------------------------------------------------|

|   | · | a      manufacturing agreement for the manufacture of PROSTASCINT with Laureate      Pharma, L.P.; |
|--------|--------|----------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | · | a      distribution services agreement with Cardinal Health 105, Inc. (formerly      CORD Logistics, Inc.) forPROSTASCINT; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------|

|   | · | a      license agreement with The Dow Chemical Company relating to Dow's      proprietary MeO-DOTA bifunctional chelant technology for use with our      CYT-500 program; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | a      purchase and supply agreement with OTN for the distribution of      CAPHOSOL; |
|--------|--------|--------------------------------------------------------------------------------------|

|   | · | a      license agreement with InPharma AS for the marketing of CAPHOSOL;      and |
|--------|--------|-----------------------------------------------------------------------------------|

|   | · | a      manufacturing agreement with Holopack for the manufacturing and supply of      CAPHOSOL. |
|--------|--------|-------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | Ÿ | our      ability to obtain patent protection for our technologies and      processes; |
|--------|--------|---------------------------------------------------------------------------------------|

|   | Ÿ | our      ability to preserve our trade secrets;and |
|--------|--------|----------------------------------------------------|

|   | Ÿ | our      ability to operate without infringing the proprietary rights of other      parties both in the United States and in foreign  countries. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Ÿ | our      patent applications will result in the issuance of  patents; |
|--------|--------|-----------------------------------------------------------------------|

|   | Ÿ | any      patents issued or licensed to us will be free from challenge and that if      challenged, would be held to bevalid; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | Ÿ | any      patents issued or licensed to us will provide commercially significant      protection for our technology, products and  processes; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------|

|   | Ÿ | other      companies will not independently develop substantially equivalent      proprietary information which is not covered by our patent      rights; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Ÿ | other      companies will not obtain access to our  know-how; |
|--------|--------|---------------------------------------------------------------|

|   | Ÿ | other      companies will not be granted patents that may prevent the      commercialization of our technology;or |
|--------|--------|-------------------------------------------------------------------------------------------------------------------|

|   | Ÿ | we      will not require licensing and the payment of significant fees or      royalties to third parties for the use of their intellectual property in      order to enable us to conduct ourbusiness. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|   | · | to      obtain sufficient capital to support the expenses of developing our      technology and commercializing ourproducts; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------|

|   | · | to      ensure that our products are safe andeffective; |
|--------|--------|---------------------------------------------------------|

|   | · | to      obtain regulatory approval for the use and sale of our      products; |
|--------|--------|-------------------------------------------------------------------------------|

|   | · | to      manufacture our products in sufficient quantities and at a reasonable      cost; |
|--------|--------|------------------------------------------------------------------------------------------|

|   | · | to      develop a sufficient market for our products;  and |
|--------|--------|------------------------------------------------------------|

|   | · | to      attract and retain qualified management, sales, technical and scientific      staff. |
|--------|--------|----------------------------------------------------------------------------------------------|

----

Table of Contents

|   | Ÿ | pharmaceutical      companies; |
|--------|--------|--------------------------------|

|   | Ÿ | biotechnology      companies; |
|--------|--------|-------------------------------|

|   | Ÿ | diagnostic      companies; |
|--------|--------|----------------------------|

|   | Ÿ | medical      device companies; |
|--------|--------|--------------------------------|

|   | Ÿ | radiopharmaceutical      distributors; |
|--------|--------|----------------------------------------|

|   | Ÿ | academic      and research institutions; and |
|--------|--------|----------------------------------------------|

|   | Ÿ | government      agencies. |
|--------|--------|---------------------------|

----

Table of Contents

----

Table of Contents

|   | Ÿ | the      USDA regulates the import, field testing and interstate movement of      specific types of genetic engineering that may be used in the creation of      transgenic plants; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | Ÿ | the      EPA regulates activity related to the invention of plant pesticides and      herbicides, which may include certain kinds of transgenic plants;      and |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Ÿ | the      FDA regulates foods derived from new plant  varieties. |
|--------|--------|-----------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Exercise      Price |   |   | Outstanding      Warrants |   |      | Aggregate      Exercise Price |   |
|---------------------|--------|--------|---------------------------|--------|-----------|-------------------------------|--------|
| $                   | 2.23   |   |                      |   | 3,256,177 |                          |   | $ | 7,264,532 |   |
| $                   | 3.32   |   |                      |   | 3,546,107 |                          |   | $ | 11,773,075 |   |
| $                   | 4.25   |   |                      |   | 1,118,868 |                          |   | $ | 4,755,189 |   |
| $                   | 6.00   |   |                      |   | 776,096   |                          |   | $ | 4,656,576 |   |
| $                   | 6.91   |   |                      |   | 315,790   |                          |   | $ | 2,182,108 |   |
| $                   | 10.97  |   |                      |   | 250,000   |                          |   | $ | 2,742,500 |   |
| $                   | 12.80  |   |                      |   | 1,272,332 |                          |   | $ | 16,285,850 |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|   | Ÿ | results      of clinical trials; |
|--------|--------|----------------------------------|

|   | Ÿ | technological      innovations or new commercialproducts; |
|--------|--------|-----------------------------------------------------------|

|   | Ÿ | changes      in governmental regulation or the status of our regulatory approvals or      applications; |
|--------|--------|---------------------------------------------------------------------------------------------------------|

|   | Ÿ | changes      in earnings; |
|--------|--------|---------------------------|

|   | Ÿ | changes      in health care policies andpractices; |
|--------|--------|----------------------------------------------------|

|   | Ÿ | developments      or disputes concerning proprietaryrights; |
|--------|--------|-------------------------------------------------------------|

|   | Ÿ | litigation      or public concern as to safety of the our potential products;      and |
|--------|--------|----------------------------------------------------------------------------------------|

|   | Ÿ | changes      in general market conditions. |
|--------|--------|--------------------------------------------|

----

Table of Contents

| Item 1B. | Unresolved      Staff Comments |
|----------|--------------------------------|

----

Table of Contents

| Item      2. | Properties |
|--------------|------------|

In 

| Item 3. | Legal      Proceedings |
|---------|------------------------|

| Item 4. | Submission      of Matters to a Vote of SecurityHolders |
|---------|---------------------------------------------------------|

----

Table of Contents

PART II

| Item 5. | Market      for the Company's Common Equity, Related Stockholder Matters and Company      Purchases of Equity Securities |
|---------|--------------------------------------------------------------------------------------------------------------------------|

| 2007                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   | High   |   |   | Low    |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|
| First      Quarter                                                                                                  |   | $      | 2.72   |   |   | $      | 1.87 |   |
| Second      Quarter                                                                                                 |   | $      | 2.59   |   |   | $      | 1.89 |   |
| Third      Quarter                                                                                                  |   | $      | 1.70   |   |   | $      | 0.76 |   |
| Fourth      Quarter                                                                                                 |   | $      | 0.80   |   |   | $      | 0.43 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   |   |   |   |   |   |   |   |
| 2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   |   |   |   |   |   |   |   |
| First      Quarter                                                                                                  |   | $      | 3.62   |   |   | $      | 2.75 |   |
| Second      Quarter                                                                                                 |   | $      | 3.73   |   |   | $      | 2.42 |   |
| Third      Quarter                                                                                                  |   | $      | 2.58   |   |   | $      | 1.91 |   |
| Fourth      Quarter                                                                                                 |   | $      | 6.87   |   |   | $      | 2.15 |   |

----

Table of Contents

| Company/Index      Name                                                                                                                                                              |   |   | 12/02 |   |   |   | 12/03  |   |   |   | 12/04  |   |   |   | 12/05  |   |   |   | 12/06  |   |   |   | 12/07  |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| CYTOGEN      Corporation                           |   |   | 100   |   |   |   | 334.77 |   |   |   | 354.46 |   |   |   | 84.31  |   |   |   | 71.69  |   |   |   | 16.31  |   |
| NASDAQ      Composite Index                                                                                                                                                          |   |   | 100   |   |   |   | 150.01 |   |   |   | 162.89 |   |   |   | 165.13 |   |   |   | 180.85 |   |   |   | 198.60 |   |
| NASDAQ      Biotechnology Index                                                                                                                                                      |   |   | 100   |   |   |   | 146.59 |   |   |   | 156.13 |   |   |   | 171.93 |   |   |   | 168.29 |   |   |   | 176.97 |   |
| NASDAQ      Pharmaceutical Index                                                                                                                                                     |   |   | 100   |   |   |   | 145.75 |   |   |   | 154.68 |   |   |   | 159.06 |   |   |   | 160.69 |   |   |   | 168.05 |   |

----

Table of Contents

Item6.                      SelectedFinancial Data

|                                                                                                                                                                                                                                                                                                                                                                     |   | Year      Ended December 31,                           |        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------|-------------|
|                                                                                                                                                                                                                                                                                                                                                                     |   | 2007                                                   |        |   | 2006 |   |   | 2005 |   |   | 2004 |   |   | 2003 |   |
|                                                                                                                                                                                                                                                                                                                                                                     |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |
| Statements      of Operations Data:                                                                                                                                                                                                                                                                                                                                      |   | (All      amounts in thousands, except per share data) |        |
| Revenues:                                                                                                                                                                                                                                                                                                                                                                |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |
| Product      revenues                                                                                     |   | $                                                      | 20,212      |   |   | $ | 17,296 |   |   | $ | 15,757 |   |   | $ | 14,480 |   |   | $ | 9,823 |   |
| Royalties                                                                                                 |   |                                                   | —     |   |   |   | — |   |   |   | — |   |   |   | — |   |   |   | 1,105 |   |
| License      and      contract                                                                            |   |                                                   | 6           |   |   |   | 11 |   |   |   | 189 |   |   |   | 139 |   |   |   | 2,914 |   |
|                                                                                                                                                                                                                                                                                                                                                                     |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total      revenues                                                                                                                |   |                                                   | 20,218      |   |   |   | 17,307 |   |   |   | 15,946 |   |   |   | 14,619 |   |   |   | 13,842 |   |
|                                                                                                                                                                                                                                                                                                                                                                     |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Operating      Expenses:                                                                                                                                                                                                                                                                                                                                                 |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Cost      of product related revenue                                                                                                                                                                                                                                                                                                                                     |   |                                                   | 13,053      |   |   |   | 10,150 |   |   |   | 9,523 |   |   |   | 9,223 |   |   |   | 6,268 |   |
| Selling,      general and administrative                                                                                                                                                                                                                                                                                                                                 |   |                                                   | 39,086      |   |   |   | 30,166 |   |   |   | 25,895 |   |   |   | 20,318 |   |   |   | 11,867 |   |
| Research      and development                                                                                                                                                                                                                                                                                                                                            |   |                                                   | 5,851       |   |   |   | 7,301 |   |   |   | 6,162 |   |   |   | 3,292 |   |   |   | 2,342 |   |
| Equity      in loss of joint venture                                                                                                                                                                                                                                                                                                                                     |   |                                                   | —     |   |   |   | 120 |   |   |   | 3,175 |   |   |   | 2,896 |   |   |   | 3,452 |   |
| Impairment      of intangible assets(1)                                                                                                                                                                                                                                                                                                                                  |   |                                                   | 1,767       |   |   |   | — |   |   |   | — |   |   |   | — |   |   |   | 115 |   |
|                                                                                                                                                                                                                                                                                                                                                                     |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total      operating expenses                                                                                                                                                                                                                                                                                                                                            |   |                                                   | 59,757      |   |   |   | 47,737 |   |   |   | 44,755 |   |   |   | 35,729 |   |   |   | 24,044 |   |
| Operating      loss                                                                        |   |                                                   | (39,539     | ) |   |   | (30,430 | ) |   |   | (28,809 | ) |   |   | (21,110 | ) |   |   | (10,202 | ) |
| Litigation      settlement,      net                                                       |   |                                                   | 3,946       |   |   |   | — |   |   |   | — |   |   |   | — |   |   |   | — |   |
| Other      income (expense), net                                                                                                                                                                                                                                                                                                                                         |   |                                                   | 1,026       |   |   |   | 1,415 |   |   |   | 598 |   |   |   | 263 |   |   |   | (44 | ) |
| Gain      on sale of equity interest in joint venture                                                                                                                                                                                                                                                                                                                    |   |                                                   | —     |   |   |   | 12,873 |   |   |   | — |   |   |   | — |   |   |   | — |   |
| Decrease      in value of warrant liabilities                                                                                                                                                                                                                                                                                                                            |   |                                                   | 8,875       |   |   |   | 1,039 |   |   |   | 1,666 |   |   |   | — |   |   |   | — |   |
|                                                                                                                                                                                                                                                                                                                                                                     |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Loss      before income      taxes                                                         |   |                                                   | (25,692     | ) |   |   | (15,103 | ) |   |   | (26,545 | ) |   |   | (20,847 | ) |   |   | (10,246 | ) |
| Income      tax      benefit                                                               |   |                                                   | —     |   |   |   | — |   |   |   | (256 | ) |   |   | (307 | ) |   |   | (888 | ) |
|                                                                                                                                                                                                                                                                                                                                                                     |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net      loss                                                                              |   | $                                                      | (25,692     | ) |   | $ | (15,103 | ) |   | $ | (26,289 | ) |   | $ | (20,540 | ) |   | $ | (9,358 | ) |
| Basic      and diluted net loss per share                                                                                                                                                                                                                                                                                                                                |   | $                                                      | (      0.79 | ) |   | $ | (0.64 | ) |   | $ | (1.54 | ) |   | $ | (1.40 | ) |   | $ | (0.92 | ) |
|                                                                                                                                                                                                                                                                                                                                                                     |   |                                                   |        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted-average      common shares outstanding, basic and diluted                                                                                                                                                                                                                                                                                                       |   |                                                   | 32,496      |   |   |   | 23,494 |   |   |   | 17,117 |   |   |   | 14,654 |   |   |   | 10,205 |   |

----

Table of Contents

|                                                                                                                                                                                                                                                                                                                                                                      |   | December      31,   |     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------|----------|
|                                                                                                                                                                                                                                                                                                                                                                      |   |                |     |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated      Balance Sheet Data:                                                                                                                                                                                                                                                                                                                                     |   | 2007                |     |   | 2006 |   |   | 2005 |   |   | 2004 |   |   | 2003 |   |
|                                                                                                                                                                                                                                                                                                                                                                      |   | (in      thousands) |     |
|                                                                                                                                                                                                                                                                                                                                                                      |   |                |     |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash,      cash equivalents and short-term investments                                                                                                                                                                                                                                                                                                                    |   | $                   | 8,914    |   |   | $ | 32,507 |   |   | $ | 30,337 |   |   | $ | 35,825 |   |   | $ | 30,215 |   |
| Total      assets                                                                           |   |                | 29,327   |   |   |   | 54,353 |   |   |   | 44,790 |   |   |   | 50,413 |   |   |   | 43,695 |   |
| Warrant      liabilities                                                                    |   |                | 995      |   |   |   | 6,464 |   |   |   | 1,869 |   |   |   | — |   |   |   | — |   |
| Other      long-term      liabilities                                                       |   |                | 66       |   |   |   | 59 |   |   |   | 46 |   |   |   | 47 |   |   |   | 2,454 |   |
| Accumulated      deficit                                                                    |   |                | (453,362 | ) |   |   | (427,670 | ) |   |   | (412,567 | ) |   |   | (386,278 | ) |   |   | (365,738 | ) |
| Stockholders'      equity                                                                   |   |                | 19,689   |   |   |   | 37,662 |   |   |   | 37,578 |   |   |   | 40,030 |   |   |   | 36,040 |   |

|   |   |
|--------|--------|

| Item 7. | Management's      Discussion and Analysis of Financial Condition and Results of      Operations |
|---------|-------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                                                                                                                                                                                                                                                                                                      |   |                                                    |    |   |   |   |    | Increase/(Decrease) |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------|---------|--------|--------|--------|---------|---------------------|--------|
|                                                                                                                                                                                                                                                                                                                      |   | 2007                                                    |    |   | 2006   |   |    |  $             |   |   |   | % |   |
|                                                                                                                                                                                                                                                                                                                      |   | (All      amounts in thousands, except percentage data) |    |
|                                                                                                                                                                                                                                                                                                                      |   |                                                    |    |   |   |   |    |                |   |   |   |   |   |
| PROSTASCINT                                                                    |   | $                                                       | 9,636   |   |   | $      | 9,125   |                |   | $ | 511 |   |   |   | 6 | % |
| QUADRAMET                                                                      |   |                                                    | 9,301   |   |   |   | 8,141   |                |   |   | 1,160 |   |   |   | 14 | % |
| CAPHOSOL                                                                       |   |                                                    | 1,275   |   |   |   | — |                |   |   | 1,275 |   |   |   | n/a |   |
| Other      product      revenue                                                |   |                                                    | — |   |   |   | 30      |                |   |   | (30 | ) |   |   | (100 | %) |
| License      and      contract                                                 |   |                                                    | 6       |   |   |   | 11      |                |   |   | (5 | ) |   |   | (45 | %) |
|                                                                                                                                                                                                                                                                                                                      |   | $                                                       | 20,218  |   |   | $      | 17,307  |                |   | $ | 2,911 |   |   |   | 17 | % |

----

Table of Contents

|                                     |   |                                                    |    |   |   |   |    | Increase/(Decrease) |   |
|------------------------------------------|--------|---------------------------------------------------------|---------|--------|--------|--------|---------|---------------------|--------|
|                                     |   | 2007                                                    |    |   | 2006   |   |    |  $             |   |   |  | % |  |
|                                     |   | (All      amounts in thousands, except percentage data) |    |
| Cost      of product revenues            |   | $                                                       | 13,053  |   |   | $      | 10,150  |                |   | $ | 2,903 |   |   |   | 29 | % |
| Selling,      general and administrative |   |                                                    | 39,086  |   |   |   | 30,166  |                |   |   | 8,920 |   |   |   | 30 | % |
| Research      and development            |   |                                                    | 5,851   |   |   |   | 7,301   |                |   |   | (1,450 | ) |   |   | (20 | %) |
| Equity      in loss of joint venture     |   |                                                    | — |   |   |   | 120     |                |   |   | (120 | ) |   |   | (100 | %) |
| Impairment      of intangible asset      |   |                                                    | 1,767   |   |   |   | — |                |   |   | 1,767 |   |   |   | n/a |   |
|                                     |   | $                                                       | 59,757  |   |   | $      | 47,737  |                |   | $ | 12,020 |   |   |   | 25 | % |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                                                                                                                                                                                                                                                                                                      |   |                                                    |        |   |   |   |   | Increase/(Decrease) |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------|-------------|--------|--------|--------|--------|---------------------|--------|
|                                                                                                                                                                                                                                                                                                                      |   | 2006                                                    |        |   | 2005   |   |   |  $             |   |   |   | % |   |
|                                                                                                                                                                                                                                                                                                                      |   | (All      amounts in thousands, except percentage data) |        |
|                                                                                                                                                                                                                                                                                                                      |   |                                                    |        |   |   |   |   |                |   |   |   |   |   |
| PROSTASCINT                                                                    |   | $                                                       |  9,125 |   |   | $      | 7,407  |                |   | $ | 1,718 |   |   |   | 23 | % |
| QUADRAMET                                                                      |   |                                                    | 8,141       |   |   |   | 8,350  |                |   |   | (209 | ) |   |   | (3 | %) |
| Other      product      revenue                                                |   |                                                    | 30          |   |   |   | --     |                |   |   | 30 |   |   |   | n/a |   |
| License      and      contract                                                 |   |                                                    | 11          |   |   |   | 189    |                |   |   | (178 | ) |   |   | (94 | %) |
|                                                                                                                                                                                                                                                                                                                      |   | $                                                       | 17,307      |   |   | $      | 15,946 |                |   | $ | 1,361 |   |   |   | 9 | % |

----

Table of Contents

|                                     |   |                                                    |   |   |   |   |   | Increase/(Decrease) |   |
|------------------------------------------|--------|---------------------------------------------------------|--------|--------|--------|--------|--------|---------------------|--------|
|                                     |   | 2006                                                    |   |   | 2005   |   |   |  $             |   |   |  | % |   |
|                                     |   | (All      amounts in thousands, except percentage data) |   |
| Cost      of product revenues            |   | $                                                       | 10,150 |   |   | $      | 9,523  |                |   | $ | 627 |   |   |   | 7 | % |
| Selling,      general and administrative |   |                                                    | 30,166 |   |   |   | 25,895 |                |   |   | 4,271 |   |   |   | 16 | % |
| Research      and development            |   |                                                    | 7,301  |   |   |   | 6,162  |                |   |   | 1,139 |   |   |   | 18 | % |
| Equity      in loss of joint venture     |   |                                                    | 120    |   |   |   | 3,175  |                |   |   | (3,055 | ) |   |   | (96 | %) |
|                                     |   | $                                                       | 47,737 |   |   | $      | 44,755 |                |   | $ | 2,982 |   |   |   | 7 | % |

----

Table of Contents

----

Table of Contents

| Contractual      Obligation          |   | Less      than 1 year           |   |   | 1      to 3 years |   |   | 4      to 5 years |   |   | More      than 5 years |   |   | Total  |    |
|--------------------------------------|--------|---------------------------------|--------|--------|-------------------|--------|--------|-------------------|--------|--------|------------------------|--------|--------|--------|---------|
|                                 |   | (All      amounts in thousands) |   |
|                                 |   |                            |   |   |              |   |   |              |   |   |                   |   |   |   |    |
| Capital      lease obligations       |   | $                               | 87     |   |              | $      | 66     |              |   | $      | —                |   |   | $      | — |   |   | $ | 153 |   |
|                                 |   |                            |   |   |              |   |   |              |   |   |                   |   |   |   |    |   |   |   |   |   |
| Facility      leases                 |   |                            | 338    |   |              |   | 282    |              |   |   | —                |   |   |   | — |   |   |   | 620 |   |
|                                 |   |                            |   |   |              |   |   |              |   |   |                   |   |   |   |    |   |   |   |   |   |
| Research      and development        |   |                            | 810    |   |              |   | 150    |              |   |   | 150                    |   |   |   | 406     |   |   |   | 1,516 |   |
|                                 |   |                            |   |   |              |   |   |              |   |   |                   |   |   |   |    |   |   |   |   |   |
| Marketing      and other obligations |   |                            | 1,671  |   |              |   | 613    |              |   |   | —                |   |   |   | — |   |   |   | 2,284 |   |
|                                 |   |                            |   |   |              |   |   |              |   |   |                   |   |   |   |    |   |   |   |   |   |
| Manufacturing      contracts(1)      |   |                            | 5,077  |   |              |   | 5,077  |              |   |   | —                |   |   |   | — |   |   |   | 10,154 |   |
|                                 |   |                            |   |   |              |   |   |              |   |   |                   |   |   |   |    |   |   |   |   |   |
| Minimum      royalty payments(2)     |   |                            | 1,000  |   |              |   | 2,000  |              |   |   | 2,000                  |   |   |   | 833     |   |   |   | 5,833 |   |
|                                 |   |                            |   |   |              |   |   |              |   |   |                   |   |   |   |    |   |   |   |   |   |
| Total(3)                             |   | $                               | 8,983  |   |              | $      | 8,188  |              |   | $      | 2,150                  |   |   | $      | 1,239   |   |   | $ | 20,560 |   |

----

Table of Contents

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   | 2007                            |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|---------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   | (All      amounts in thousands) |    |
| Net      loss                                                                                                                     |   | $                               | (25,692 | ) |
| Adjustments      to reconcile net loss to net cash used inoperating    activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |   |                            | (5,437  | ) |
| Net      cash used in operating      activities                                                                                   |   |                            | (31,129 | ) |
| Net      cash used in investing      activities                                                                                   |   |                            | (2,040  | ) |
| Net      cash provided by financing activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |   |                            | 9,576   |   |
| Net      decrease in cash and cash equivalents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |   | $                               | (23,593 | ) |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

Item 7A.

| Item 8. | Financial      Statements and Supplementary Data |
|---------|--------------------------------------------------|

The

----

Table of Contents

| Item 9. | Changes      in and Disagreements with Accountants on Accounting and Financial      Disclosure |
|---------|------------------------------------------------------------------------------------------------|

Not 

| Item 9A. | Controls      and Procedures |
|----------|------------------------------|

|   | (a) | Disclosure      Controls and Procedures |
|--------|-----|-----------------------------------------|

|  (b) | Internal      Controls Over Financial Reporting |
|-----------|-------------------------------------------------|

|   | (1) | Management's      Annual Report on Internal Control Over Financial  Reporting |
|--------|-----|-------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item      9B. | Other      Information |
|---------------|------------------------|

N

PART III

| Item 10. | Directors,      Executive Officers and CorporateGovernance |
|----------|------------------------------------------------------------|

Th

| Item 11. | Executive      Compensation |
|----------|-----------------------------|

| Item 12. | Security      Ownership of Certain Beneficial Owners and Management and Related      Stockholder Matters |
|----------|----------------------------------------------------------------------------------------------------------|

| Item 13. | Certain      Relationships and Related Transactions, and Director      Independence |
|----------|-------------------------------------------------------------------------------------|

----

Table of Contents

| Item 14. | Principal      Accountant Fees and Services |
|----------|---------------------------------------------|

Thediscussion under the heading "Independent Auditors' Fees and Services" in ourdefinitive proxy statement for the 2008 Annual Meeting of Stockholders isincorporated herein by reference to such proxy statement.

PART IV

| Item 15. | Exhibits      and Financial Statement Schedules. |
|----------|--------------------------------------------------|

| Exhibit No. |   |                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |   |
| 3.1.1       |   | Restated      Certificate of Incorporation of Cytogen Corporation, as      amended.  Filed as an exhibit to the Company's Quarterly Report      on Form 10-Q for the quarter ended June 30, 1996, filed with the      Commission on August 2, 1996, and incorporated herein by      reference.                                                                                |
|        |   |
| 3.1.2       |   | Certificate      of Amendment to the Restated Certificate of Incorporation of Cytogen      Corporation, as amended.  Filed as an exhibit to the Company's      Quarterly Report on Form 10-Q for the quarter ended June 30, 2000, filed      with the Commission on August 11, 2000, and incorporated herein by      reference.                                               |
|        |   |
| 3.1.3       |   | Certificate      of Amendment to the Restated Certificate of Incorporation, as amended, as      filed with the Secretary of State of the State of Delaware on October 25,      2002.  Filed as an exhibit to the Company's Current Report on      Form 8-K, dated October 25, 2002, filed with the Commission on October 25,      2002, and incorporated herein by reference. |
|        |   |
| 3.1.4       |   | Certificate      of Designations of Series C Junior Participating Preferred Stock of      Cytogen Corporation.  Filed as an exhibit to the Company's      Registration Statement on Form S-8 (Reg. No. 333-59718), filed with the      Commission on April 27, 2001, and incorporated herein by      reference.                                                               |
|        |   |
| 3.1.5       |   | Certificate      of Amendment to the Restated Certificate of Incorporation dated June 15,      2005.  Filed as an exhibit to the Company's Quarterly Report on      Form 10-Q for the quarter ended June 30, 2005, filed with the Commission      on August 9, 2005, and incorporated herein byreference.                                                                     |
|        |   |                                                                                                                                                                                                                                                                                                                                                                                    |

----

Table of Contents

| Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 3.1.6            |   | Certificate      of Amendment to Restated Certificate of Incorporation dated June 13,      2007.  Filed as an exhibit to the Company’s Quarterly Report on      Form 10-Q ended June 30, 2007, filed with the Commission on August 9, 2007      and incorporated herein by reference.                                                                                                                                                                                                                                                                                                                                                                              |
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 3.2              |   | By-Laws      of Cytogen Corporation, as amended and restated.  Filed as an      exhibit to the Company's Current Report on Form 8-K, filed with the      Commission on October 19, 2006, and incorporated herein by      reference.                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|             |   |
| 4.1.1            |   | Amended      and Restated Rights Agreement, dated as of October 19, 1998 between      Cytogen Corporation and Chase Mellon Shareholder Services, L.L.C., as      rights agent.  The Amended and Restated Rights Agreement      includes the Form of Certificate of Designations of Series C Junior      Participating Preferred Stock as Exhibit A, the form of Right Certificate      as Exhibit B and the Summary of Rights as Exhibit C.  Filed as      an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter      ended September 30, 1998, filed with the Commission on November 13, 1998,      and incorporated herein by reference. |
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 4.1.2            |   | Agreement      for Substitution and Amendment of Rights Agreement by and between Cytogen      Corporation and American Stock Transfer & Trust Company dated      September 1, 2004.  Filed as an exhibit to the Company's Current      Report on Form 8-K, dated September 1, 2004, filed with the Commission on      September 2, 2004, and incorporated herein byreference.                                                                                                                                                                                                                                                                                        |
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.1.1           |   | 1988      Stock Option Plan for Non-Employee Directors.  Filed as an      exhibit to the Company's Registration Statement on Form S-8 (Reg. No.      33-30595), filed with the Commission on August 18, 1989, and incorporated      herein by reference. +                                                                                                                                                                                                                                                                                                                                                                                                               |
|             |   |
| 10.1.2           |   | Amendment      No. 2 to the Cytogen Corporation 1988 Stock Option Plan for Non-Employee      Directors dated May 22, 1996.  Filed as an exhibit to the      Company's Quarterly Report on Form 10-Q for the quarter ended June 30,      1996, filed with the Commission on August 2, 1996, and incorporated herein      by reference. +                                                                                                                                                                                                                                                                                                                                  |
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.2             |   | 1989      Stock Option Policy for Outside Consultants.  Filed as an      exhibit to Amendment No. 1 to the Company's Registration Statement on Form      S-1 (Reg. No. 33-31280), and incorporated herein by reference.      +                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.3.1           |   | License      Agreement dated March 31, 1993 between Cytogen Corporation and The Dow      Chemical Company.  Filed as an exhibit to Amendment No. 1 to the      Company's Quarterly Report on Form 10-Q for the quarter ended July 3,      1993, filed with the Commission on October 13, 1993, and incorporated      herein by reference.*                                                                                                                                                                                                                                                                                                                               |

----

Table of Contents

| Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                                                                                                                     |
|------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |
| 10.3.2           |   | Amendment      of the License Agreement between Cytogen Corporation and The Dow Chemical      Company dated September 5, 1995.  Filed as an exhibit to the      Company's Quarterly Report on Form 10-Q for the quarter ended March 31,      1996, filed with the Commission on May 9, 1996, and incorporated herein by      reference.*                                                                       |
|             |   |
| 10.3.3           |   | Second      Amendment to the License Agreement between Cytogen Corporation and The Dow      Chemical Company dated May 20, 1996.  Filed as an exhibit to      Amendment No. 1 to the Company's Quarterly Report on Form 10-Q for the      quarter ended June 30, 1996, filed with the Commission on August 2, 1996,      and incorporated herein by reference.*                                                |
|             |   |
| 10.4             |   | License      Agreement, dated March 10, 1993, between Cytogen Corporation and The      University of North Carolina at Chapel Hill, as amended.  Filed      as an exhibit to the Company's Annual Report on Form 10-K for the year      ended December 31, 1994, filed with the Commission on March 17, 1995, and      incorporated herein by reference.*                                                      |
|             |   |
| 10.5             |   | Option      and License Agreement, dated July 1, 1993, between Cytogen Corporation and      Sloan-Kettering Institute for Cancer Research.  Filed as an      exhibit to the Company's Annual Report on Form 10-K for the year ended      December 31, 1994, filed with the Commission on March 17, 1995, and      incorporated herein by reference.*                                                           |
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 10.6             |   | Horosziewicz-Cytogen      Agreement, dated April 20, 1989, between Cytogen Corporation and Julius S.      Horosziewicz, M.D., DMSe.  Filed as an exhibit to the Company' s      Annual Report on Form 10-K for the year ended December 31, 1995, filed      with the Commission on March 28, 1996, and incorporated herein by      reference.*                                                                 |
|             |   |
| 10.7.1           |   | Stock      Exchange Agreement among Cytogen Corporation and the Stockholders and      Debtholders of Prostagen, Inc.  Filed as an exhibit to the      Company's Registration Statement on Form S-3 (Reg. No. 333-83215) dated      July 19, 1999, as amended, filed with the Commission on July 20, 1999, and      incorporated herein by reference.                                                           |
|             |   |                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 10.7.2           |   | Addendum      to Stock Exchange Agreement among Cytogen Corporation and the Shareholders      and Debtholders of Prostagen, Inc. dated as of May 14, 2002, and amended      as of August 13, 2002.  Filed as an exhibit to the Company's      Quarterly Report on Form 10-Q for the quarter ended June 30, 2002, filed      with the Commission on August 14, 2002, and incorporated herein by      reference. |

----

Table of Contents

|             |   |                                                                                                                                                                                                                                                                                                                                                                 |
|------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                                                                 |
|             |   |                                                                                                                                                                                                                                                                                                                                                                 |
| 10.7.3           |   | Addendum      No. 2 to Stock Exchange Agreement among Cytogen Corporation and the      Stockholders and Debtholders of Prostagen, Inc.  Filed as an      exhibit to the Company's Current Report on Form 8-K dated November 19,      2004, filed with the Commission on November 22, 2004, and incorporated      herein by reference.                      |
|             |   |                                                                                                                                                                                                                                                                                                                                                                 |
| 10.8             |   | AxCell      Biosciences Corporation Stock Option Plan.  Filed as an exhibit      to the Company's Annual Report on Form 10-K for the year ended December      31, 1999, filed with the Commission on March 28, 2000, and incorporated      herein by reference. +                                                                                          |
|             |   |                                                                                                                                                                                                                                                                                                                                                                 |
| 10.9             |   | Written      Compensatory Agreement by and between Cytogen Corporation and H. Joseph      Reiser dated August 24, 1998, as revised on July 11,      2000.  Filed as an exhibit to the Company's Registration      Statement on Form S-8 (Reg. No. 333-48454), filed with the Commission on      October 23, 2000, and incorporated herein by reference.  + |
|             |   |
| 10.10            |   | Written      Compensatory Agreement by and between Cytogen Corporation and Lawrence      Hoffman dated July 10, 2000.  Filed as an exhibit to the      Company's Registration Statement on Form S-8 (Reg. No. 333-48454), filed      with the Commission on October 23, 2000, and incorporated herein by      reference. +                                 |
|             |   |
| 10.11            |   | Cytogen      Corporation Stock Payment Program Bonus Plan.  Filed as an      exhibit to the Company's Registration Statement on Form S-8 (Reg. No.      333-58384), filed with the Commission on April 6, 2001, and incorporated      herein by reference. +                                                                                               |
|             |   |
| 10.12            |   | MFS      Fund Distributors, Inc. 401(K) Profit Sharing Plan and      Trust.  Filed as an exhibit to the Company's Registration      Statement on Form S-8 (Reg. No. 333-59718), filed with the Commission on      April 27, 2001, and incorporated herein by reference. +                                                                                  |
|             |   |
| 10.13            |   | Adoption      Agreement for MFS Fund Distributors, Inc. Non-Standardized 401(K) Profit      Sharing Plan and Trust, with amendments.  Filed as an exhibit to      the Company's Registration Statement on Form S-8 (Reg. No. 333-59718),      filed with the Commission on April 27, 2001, and incorporated herein by      reference.                      |
|             |   |

| 10.14  |   | Cytogen      Corporation Performance Bonus Plan with Stock Payment      Program.  Filed as an exhibit to Company's Registration      Statement on Form S-8 (Reg. No. 333-75304), filed with the Commission on      December 17, 2001, and incorporated herein by reference.  + |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |

----

Table of Contents

| Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                                                          |
|------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |                                                                                                                                                                                                                                                                                                                                                          |
| 10.15            |   | Share      Purchase Agreement by and between Cytogen Corporation and the State of      Wisconsin Investment Board dated as of January 18, 2002.  Filed      as an exhibit to the Company's Current Report on Form 8-K, dated January      18, 2002, filed with the Commission on January 24, 2002, and incorporated      herein by reference.       |
|             |   |
| 10.16            |   | Form      of Executive Change of Control Severance Agreement by and between Cytogen      Corporation and each of its Executive Officers.  Filed as an      exhibit to the Company's Annual Report on Form 10-K for the year ended      December 31, 2001, filed with the Commission on March 28, 2002, and      incorporated herein by reference. + |
|             |   |
| 10.17.1          |   | Sublease      Agreement by and between Cytogen Corporation and Hale and Dorr LLP dated      as of May 23, 2002.  Filed as an exhibit to the Company's      Quarterly Report on Form 10-Q for the quarter ended June 30, 2002, filed      with the Commission on August 14, 2002, and incorporated herein by      reference.                         |
|             |   |                                                                                                                                                                                                                                                                                                                                                          |
| 10.17.2          |   | First      Amendment to Sublease Agreement by and between Cytogen Corporation and      Hale and Dorr LLP dated February 10, 2004.  Filed as an exhibit      to the Company's Quarterly Report on Form 10-Q for the quarter ended March      31, 2004, filed with the Commission on May 7, 2004, and incorporated      herein by reference.          |
|             |   |                                                                                                                                                                                                                                                                                                                                                          |
| 10.18            |   | Cytogen      Corporation Amended and Restated 1995 Stock Option Plan.  Filed      as an exhibit to the Company's Annual Report on Form 10-K for the year      ended December 31, 2002, filed with the Commission on March 31, 2003, and      incorporated herein by reference. +                                                                    |
|             |   |
| 10.19            |   | Amended      and Restated 1999 Stock Option Plan for Non-Employee      Directors.  Filed as an exhibit to the Company's Annual Report      on Form 10-K for the year ended December 31, 2002, filed with the      Commission on March 31, 2003, and incorporated herein by reference.      +                                                        |
|             |   |                                                                                                                                                                                                                                                                                                                                                          |
|  10.20      |   |  Written      Compensatory Agreement by and between Cytogen Corporation and Michael D.      Becker dated December 17, 2002.  Filed as an exhibit to the Company's      Annual Report on Form 10-K for the year ended December 31, 2002, filed      with the Commission on March 31, 2003, and incorporated herein by      reference. +              |
|             |   |                                                                                                                                                                                                                                                                                                                                                          |
| 10.21            |   |  Securities      Purchase Agreement by and among Cytogen Corporation and certain purchasers      of the Company's common stock dated June 6, 2003.  Filed as an      exhibit to the Company's Current Report on Form 8-K dated June 6, 2003,      filed with the Commission on June 9, 2003, and incorporated herein by      reference.             |
|             |   |

----

Table of Contents

| Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                                                             |
|------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |                                                                                                                                                                                                                                                                                                                                                             |
| 10.22            |   | Form      of Common Stock Purchase Warrant issued by the Company in favor of certain      purchasers of the Company's common stock dated June 6,      2003.  Filed as an exhibit to the Company's Current Report on      Form 8-K dated June 6, 2003, filed with the Commission on June 9, 2003,      and incorporated herein by reference.            |
|             |   |
| 10.23            |   | Registration      Rights Agreement by and among the Company and certain purchasers of the      Company's common stock dated June 6, 2003.  Filed as an exhibit      to the Company's Current Report on Form 8-K dated June 6, 2003, filed with      the Commission on June 9, 2003, and incorporated herein by      reference.                         |
|             |   |
| 10.24            |   | Securities      Purchase Agreement by and among Cytogen Corporation and certain purchasers      of the Company's common stock dated July 10, 2003.  Filed as an      exhibit to the Company's Current Report on Form 8-K dated July 10, 2003,      filed with the Commission on July 11, 2003, and incorporated herein by      reference.              |
|             |   |
| 10.25            |   | Form      of Common Stock Purchase Warrant issued by Cytogen Corporation in favor of      certain purchasers of the Company's common stock dated July 10,      2003.  Filed as an exhibit to the Company's Current Report on      Form 8-K dated July 10, 2003, filed with the Commission on July 11, 2003,      and incorporated herein by reference. |
|             |   |
| 10.26            |   | Registration      Rights Agreement by and among Cytogen Corporation and certain purchasers      of the Company's common stock dated July 10, 2003.  Filed as an      exhibit to the Company's Current Report on Form 8-K dated July 10, 2003,      filed with the Commission on July 11, 2003, and incorporated herein by      reference.              |

| 10.27  |   | Share      Purchase Agreement by and among Cytogen Corporation and certain purchasers      of the Company's common stock dated November 6, 2003.  Filed as      an exhibit to the Company's Current Report on Form 8-K dated November 6,      2003, filed with the Commission on November 7, 2003, and incorporated      herein by reference.     |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
| 10.28  |   | Termination      Agreement between Cytogen Corporation and Berlex Laboratories, Inc., dated      June 16, 2003.  Filed as an exhibit to the Company's Quarterly      Report on Form 10-Q for the quarter ended September 30, 2003, filed with      the Commission on November 12, 2003, and incorporated herein by reference.      **             |
|   |   |                                                                                                                                                                                                                                                                                                                                                        |
| 10.29  |   | Assignment      Agreement between Cytogen Corporation and Berlex Laboratories, Inc., dated      August 1, 2003.  Filed as an exhibit to the Company's Quarterly      Report on Form 10-Q for the quarter ended September 30, 2003, filed with      the Commission on November 12, 2003, and incorporated herein by reference.      **   |

----

Table of Contents

| Exhibit      No. |   |
|------------------|--------|
|             |   |
| 10.30            |   | Placement      Agency Agreement by and among Cytogen Corporation, CIBC World Markets      Corp., JMP Securities LLC and ThinkEquity Partners LLC dated April 14,      2004.  Filed as an exhibit to the Company's Current Report on      Form 8-K dated April 14, 2004, filed with the Commission on April 15,      2004, and incorporated herein by reference. |
|             |   |   |
| 10.31            |   | Manufacturing      and Supply Agreement by and between Cytogen Corporation and Bristol-Myers      Squibb Medical Imaging, Inc. effective as of January 1,      2004.  Filed as an exhibit to the Company's Quarterly Report on      Form 10-Q for the quarter ended March 31, 2004, filed with the Commission      on May 7, 2004, and incorporated herein by reference.** |
|             |   |
| 10.32            |   | Cytogen      Corporation 2004 Stock Incentive Plan.  Filed as an exhibit to      the Company's Quarterly Report on Form 10-Q for the quarter ended June 30,      2004, filed with the Commission on August 9, 2004, and incorporated herein      by reference. + |
|             |   |   |
| 10.33            |   | Cytogen      Corporation 2004 Non-Employee Director Stock Incentive      Plan.  Filed as an exhibit to the Company's Quarterly Report on      Form 10-Q for the quarter ended June 30, 2004, filed with the Commission      on August 9, 2004, and incorporated herein by reference.  + |
|             |   |   |
| 10.34            |   | Warrant      Agreement, dated June 10, 2003, between Cytogen Corporation and Howard      Soule, Ph.D.  Filed as an exhibit to the Company's Registration      Statement on Form S-8 (Reg. No. 333-121320), filed with the Commission on      December 16, 2004, and incorporated herein by reference.  + |
|             |   |   |
| 10.35            |   | Cytogen      Corporation Employee Stock Purchase Plan, amended as of February      2005.  Filed as an exhibit to the Company's Current Report on      Form 8-K dated February 8, 2005, filed with the Commission on February 10,      2005, and incorporated herein by reference. + |
|             |   |   |
| 10.36            |   | Form      of Securities Purchase Agreement by and among the Company and the      Purchasers dated July 19, 2005.  Filed as an exhibit to the      Company's Current Report on Form 8-K, filed with the Commission on July      20, 2005, and incorporated herein by reference. |
|             |   |   |
| 10.37            |   | Form      of Common Stock Purchase Warrant issued by the Company in favor of each      Purchaser dated July 19, 2005.  Filed as an exhibit to the      Company's Current Report on Form 8-K, filed with the Commission on July      20, 2005, and incorporated herein by reference. |
|             |   |

----

Table of Contents

|  Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.38                  |   | Cytogen      Corporation 2005 Employee Stock Purchase Plan.  Filed as an      exhibit to the Company's Current Report on Form 8-K, filed with the      Commission on September 27, 2005, and incorporated herein by reference.      +                                                                                                                                           |
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.39                  |   | Form      of Securities Purchase Agreement by and among the Company and the      Purchasers dated December 13, 2005.  Filed as an exhibit to the      Company's Current Report on Form 8-K, filed with the Commission on      December 14, 2005, and incorporated herein byreference.                                                                                           |
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.40                  |   | Form      of Common Stock Purchase Warrant issued by the Company in favor of each      Purchaser dated December 13, 2005.  Filed as an exhibit to the      Company's Current Report on Form 8-K, filed with the Commission on      December 14, 2005, and incorporated herein byreference.                                                                                      |
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.41                  |   | Engagement      Agreement dated December 13, 2005 between Cytogen Corporation and Rodman      & Renshaw, LLC.  Filed as an exhibit to the Company's      Current Report on Form 8-K/A, filed with the Commission on December 14,      2005, and incorporated herein by reference.                                                                                           |
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.42                  |   | Cytogen      Corporation 2006 Equity Compensation Plan.  Filed as an exhibit      to the Company's Quarterly Report on Form 10-Q for the quarter ended March      31, 2006, filed with the Commission on May 10, 2006, and incorporated      herein by reference. +                                                                                                             |
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.43                  |   | Membership      Interest Purchase Agreement dated as of April 20, 2006 between the Company      and Progenics Pharmaceutical, Inc.  Filed as an exhibit to the      Company's Quarterly Report on Form 10-Q for the quarter ended March 31,      2006, filed with the Commission on May 10, 2006, and incorporated herein      by reference.                                    |
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.44                  |   | Amended      and Restated PSMA/PSMP License Agreement dated April 20, 2006 among the      Company, Progenics Pharmaceuticals, Inc. and PSMA Development Company      LLC.** Filed      as an exhibit to the Company's Quarterly Report on Form 10-Q for the      quarter ended March 31, 2006, filed with the Commission on May 10, 2006,      and incorporated herein by reference. |
|                   |   |                                                                                                                                                                                                                                                                                                                                                                                      |
| 10.45                  |   | Exclusive      Distribution Agreement dated as of April 21, 2006 between the Company and      Savient Pharmaceuticals, Inc.      ** Filed      as an exhibit to the Company's Quarterly Report on Form 10-Q for the      quarter ended March 31, 2006, filed with the Commission on May 10, 2006,      and incorporated herein byreference.                                          |

----

Table of Contents

| Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                                                                     |
|------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |                                                                                                                                                                                                                                                                                                                                                                     |
| 10.46            |   | Manufacture      and Supply Agreement dated April 21, 2006 between the Company, Savient      Pharmaceuticals, Inc. and Rosemont Pharmaceuticals Limited.** Filed      as an exhibit to the Company's Quarterly Report on Form 10-Q for the      quarter ended March 31, 2006, filed with the Commission on May 10, 2006,      and incorporated herein by reference. |
|             |   |                                                                                                                                                                                                                                                                                                                                                                     |
| 10.47            |   | Product      Purchase and Supply Agreement dated as of June 20, 2006 between the      Company and Oncology Therapeutics Network, J.V.  Filed as an      exhibit to the Company's Quarterly Report on Form 10-Q for the quarter      ended June 30, 2006, filed with the Commission on August 9, 2006, and      incorporated herein by reference.               |
|             |   |                                                                                                                                                                                                                                                                                                                                                                     |
| 10.48            |   | Manufacturing      Agreement dated September 29, 2006 by and between the Company and Laureate      Pharma, Inc.      **  Filed as an exhibit to the Company's Quarterly Report      on Form 10-Q, filed with the Commission on November 9, 2006, and      incorporated herein by reference.                                                                    |
|             |   |                                                                                                                                                                                                                                                                                                                                                                     |
|  10.49.1    |   | Product      License and Assignment Agreement dated as of October 11, 2006 by and among      the Company, InPharma AS, and InPharma, Inc.      **  Filed as an exhibit to the Company's Quarterly Report      on Form 10-Q, filed with the Commission on November 9, 2006, and      incorporated herein by reference.                                          |
|             |   |                                                                                                                                                                                                                                                                                                                                                                     |
|  10.49.2    |   | Amendment      No. 1 to Product License and Assignment Agreement dated August 30, 2007      between the Company and InPharma AS.*  Filed as an exhibit to      the Company’s Quarterly Report on Form 10-Q for the quarter ended      September 30, 2007, filed with the Commission on November 14, 2007, and      incorporated herein by reference.     |
|             |   |                                                                                                                                                                                                                                                                                                                                                                     |
| 10.50            |   | Securities      Purchase Agreement dated as of November 1, 2006, among the Company and      certain Purchasers.  Filed as an exhibit to the Company's      Current Report on Form 8-K, filed with the Commission on November 9, 2006,      and incorporated herein by reference.                                                                               |
|             |   |                                                                                                                                                                                                                                                                                                                                                                     |
| 10.51            |   | Form      of Common Stock Purchase Warrant issued by the Company in favor of certain      Purchasers.  Filed as an exhibit to the Company's Current Report      on Form 8-K, filed with the Commission on November 9, 2006, and      incorporated herein by reference.                                                                                         |

----

Table of Contents

| Exhibit      No. |   |                                                                                                                                                                                                                                                                                                                  |
|------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |                                                                                                                                                                                                                                                                                                                  |
| 10.52            |   | Form      of Registration Rights Agreement among the Company and certain      Purchasers.  Filed as an exhibit to the Company's Current Report      on Form 8-K, filed with the Commission on November 9, 2006, and      incorporated herein by reference.                                                  |
|             |   |                                                                                                                                                                                                                                                                                                                  |
| 10.53            |   | Settlement      and Release Agreement dated February 15, 2007 between the Company and      Advanced Magnetics, Inc.  Filed as an exhibit to the Company’s      Annual Report on Form 10-K filed with the Commission on March 16, 2007 and      incorporated herein by reference.                      |
|             |   |                                                                                                                                                                                                                                                                                                                  |
| 10.54            |   | Contract      Manufacturing Agreement dated as of January 8, 2007 between the Company      and Holopack Verpackungstechnik GmbH.**  Filed      as an exhibit to the Company’s Annual Report on Form 10-K filed with the      Commission on March 16, 2007, and incorporated herein by      reference. |

| 10.55  |   | Securities      Purchase Agreement between the Company and each of the Purchasers dated as      of June 28, 2007. Filed as an exhibit to the Company's Current Report on      Form 8-K, filed with the Commission on July 2, 2007, and incorporated      herein by reference.                                         |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                  |
| 10.56  |   | Form      of Common Stock Purchase Warrant issued by the Company in favor of each      Purchaser. Filed as an exhibit to the Company's Current Report on Form      8-K, filed with the Commission on July 2, 2007, and incorporated herein by      reference.                                                         |
|   |   |                                                                                                                                                                                                                                                                                                                  |
| 10.57  |   | Registration Rights Agreement      between the Company and each of the Purchasers dated as of June 28,      2007. Filed as an exhibit to the Company's Current Report on Form 8-K,      filed with the Commission on July 2, 2007, and incorporated herein by      reference.                          |
|   |   |                                                                                                                                                                                                                                                                                                                  |
| 10.58  |   | Engagement      Agreement between the Company, Rodman & Renshaw, LLC and Roth Capital      Partners, LLC. Filed as an exhibit to the Company's Current Report on      Form 8-K, filed with the Commission on July 11, 2007, and incorporated      herein by reference.                                       |
|   |   |                                                                                                                                                                                                                                                                                                                  |
| 10.59  |   | Cytogen      Corporation 2004 Non-Employee Director Stock Incentive Plan, as      amended.  Filed as an exhibit to the Company’s Quarterly Report      on Form 10-Q for the quarter ended June 30, 2007, filed with the      Commission on August 9, 2007, and incorporated herein by      reference. |
|   |   |                                                                                                                                                                                                                                                                                                                  |
| 23.1   |   | Consent      of KPMG LLP. Filed herewith.                                                                                                                                                                                                                                                                             |

----

Table of Contents

| Exhibit      No. |   |                                                                                                                                                                                                                                                                  |
|------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |                                                                                                                                                                                                                                                                  |
| 23.2             |   | Consent      of PricewaterhouseCoopers LLP. Filed herewith                                                                                                                                                                                                       |
|             |   |                                                                                                                                                                                                                                                                  |
| 24               |   | Power      of Attorney (contained on signature page attached  hereto)                                                                                                                                                                                                 |
|             |   |                                                                                                                                                                                                                                                                  |
| 31.1             |   | Certification      of President and Chief Executive Officer pursuant to Rule 13a-14(a) or      15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to      Section 302 of the Sarbanes-Oxley Act of 2002. Filed    herewith.                        |
|             |   |                                                                                                                                                                                                                                                                  |
| 31.2             |   | Certification      of Senior Vice President, Finance and Chief Financial Officer pursuant to      Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as      adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed      herewith. |
|             |   |                                                                                                                                                                                                                                                                  |
| 32.1             |   | Certification      of President and Chief Executive Officer pursuant to 18 U.S.C Section      1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of      2002. Filed herewith.                                                                        |
|             |   |                                                                                                                                                                                                                                                                  |
| 32.2             |   | Certification      of Senior Vice President, Finance and Chief Financial Officer pursuant to      18 U.S.C Section 1350, as adopted pursuant to Section 906 of the      Sarbanes-Oxley Act of 2002. Filed herewith.                                                   |
|             |   |                                                                                                                                                                                                                                                                  |

|   | (b) | Exhibits: |
|--------|-----|-----------|

|   | The      Exhibits filed with this Form 10-K are listed above in response to Item      15(a)(3). |
|--------|-------------------------------------------------------------------------------------------------|

|   | (c) | Financial      Statement Schedules: |
|--------|-----|-------------------------------------|

|   | None. |
|--------|-------|

----

Table of Contents

SIGNATURES

|   | CYTOGEN      CORPORATION |
|--------|--------------------------|
|   |                     |   |
|   | By:                      | /s/ KEVIN      G. LOKAY |
|   |                     | Kevin      G. Lokay, |
|   |                     | President      and Chief Executive Officer |

----

Table of Contents

|      | Signature                                  |   | Title                                                                            |   | Date                |
|-----------|--------------------------------------------|--------|----------------------------------------------------------------------------------|--------|---------------------|
|      |                                       |   |                                                                             |   |                |
| By:       | /s/  KEVIN      G. LOKAY         |   | President      and Chief Executive Officer                                       |   | March      14, 2008 |
|      | Kevin      G. Lokay                        |   | (Principal      Executive Officer and Director)                                  |   |                |
|      |                                       |   |                                                                             |   |                |
|  By: |  /s/  KEVIN      J. BRATTON |   | Senior      Vice President, Finance, and Chief Financial Officer      (Principal |   | March      14, 2008 |
|      | Kevin      J. Bratton                      |   |      Financial      and Accounting Officer)             |   |                |
|      |                                       |   |                                                                             |   |                |
| By:       | /s/  JOHN      E. BAGALAY, JR.   |   | Director                                                                         |   | March      14, 2008 |
|      | John      E. Bagalay, Jr.                  |   |                                                                             |   |                |
|      |                                       |   |                                                                             |   |                |
| By:       | /s/  ALLEN      BLOOM            |   | Director                                                                         |   | March      14, 2008 |
|      | Allen      Bloom                           |   |                                                                             |   |                |
|      |                                       |   |                                                                             |   |                |
| By:       | /s/      STEPHEN K. CARTER                 |   | Director                                                                         |   | March      14, 2008 |
|      | Stephen      K. Carter                     |   |                                                                             |   |                |
|      |                                       |   |                                                                             |   |                |
| By:       | /s/  JAMES      A. GRIGSBY       |   | Director      and Chairman of the Board                                          |   | March      14, 2008 |
|      | James      A. Grigsby                      |   |                                                                             |   |                |
|      |                                       |   |                                                                             |   |                |
| By:       | /s/  ROBERT      F. HENDRICKSON  |   | Director                                                                         |   | March      14, 2008 |
|      | Robert      F. Hendrickson                 |   |                                                                             |   |                |
|      |                                       |   |                                                                             |   |                |

----

Table of Contents

| By:    | /s/  DENNIS      H. LANGER  |   | Director |   | March      14, 2008 |
|--------|---------------------------------------|--------|----------|--------|---------------------|
|   | Dennis      H. Langer                 |   |     |   |                |
|   |                                  |   |     |   |                |
| By:    | /s/  JOSEPH      A. MOLLICA |   | Director |   | March      14, 2008 |
|   | Joseph      A. Mollica                |   |     |   |                |

----

Table of Contents

Form 10-K Item 15(a)(1) and (2)

CYTOGEN CORPORATION AND SUBSIDIARIES

| Report of Independent Registered Public Accounting      Firm                                                                                | F-2    |
|---------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Report of Independent Registered Public Accounting Firm      (PricewaterhouseCoopers LLP)                                                   | F-4    |
| Consolidated      Financial Statements:                                                                                                     |   |
| Consolidated      Balance Sheets as of December 31, 2007 and 2006                                                                           | F-5    |
| Consolidated      Statements of Operations–Years Ended December 31, 2007, 2006      and  2005                               | F-6    |
| Consolidated      Statements of Stockholders' Equity and Comprehensive      Loss–Years Ended December 31, 2007, 2006 and    2005 | F-7    |
| Consolidated      Statements of Cash Flows–Years Ended December 31, 2007, 2006      and 2005                                     | F-8    |
| Notes to      Consolidated Financial Statements                                                                                             | F-9    |

----

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLICACCOUNTING FIRM

----

Table of Contents

----

Table of Contents

Report

----

Table of Contents

CYTOGEN CORPORATION AND SUBSIDIARIES

|                                                                                                                                                                                                      |   | December      31, |     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------|----------|
|                                                                                                                                                                                                      |   | 2007              |     |   | 2006 |   |
|                                                                                                                                                                                                      |   |              |     |   |   |   |
| ASSETS:                                                                                                                                                                                                   |   |              |     |   |   |   |
| Current      assets:                                                                                                                                                                                      |   |              |     |   |   |   |
| Cash      and cash equivalents                                                                                                                                                                            |   | $                 | 8,914    |   |   | $ | 32,507 |   |
| Restricted      cash                                                                                                                                                                                      |   |              | —  |   |   |   | 1,100 |   |
| Accounts      receivable, net                                                                                                                                                                             |   |              | 2,747    |   |   |   | 2,113 |   |
| Inventories                                                                                                                                                                                               |   |              | 4,635    |   |   |   | 2,538 |   |
| Prepaid      expenses                                                                                                                                                                                     |   |              | 1,070    |   |   |   | 1,571 |   |
| Other      current assets                                                                                                                                                                                 |   |              | 121      |   |   |   | 156 |   |
| Total      current assets                                                                                                                                                                                 |   |              | 17,487   |   |   |   | 39,985 |   |
| Property      and equipment, less accumulated depreciation and amortization of $1,662      and $1,409 at December 31, 2007 and 2006, respectively                                                         |   |              | 1,046    |   |   |   | 691 |   |
| Product      license fees, less accumulated amortization of $3,547 and $2,577, at      December 31, 2007 and 2006, respectively                                                                           |   |              | 8,842    |   |   |   | 11,612 |   |
| Other      assets                                                                                                                                                                                         |   |              | 1,952    |   |   |   | 2,065 |   |
|                                                                                                                                                                                                      |   | $                 | 29,327   |   |   | $ | 54,353 |   |
| LIABILITIES      AND STOCKHOLDERS' EQUITY:                                                                                                                                                                |   |              |     |   |   |   |   |   |
| Current      liabilities:                                                                                                                                                                                 |   |              |     |   |   |   |   |   |
| Current      portion of long-term liabilities                                                                                                                                                             |   | $                 | 87       |   |   | $ | 64 |   |
| Accounts      payable and accrued liabilities                                                                                                                                                             |   |              | 8,490    |   |   |   | 10,104 |   |
| Total      current liabilities                                                                                                                                                                            |   |              | 8,577    |   |   |   | 10,168 |   |
| Warrant      liabilities                                                                                                                                                                                  |   |              | 995      |   |   |   | 6,464 |   |
| Other      long-term liabilities                                                                                                                                                                          |   |              | 66       |   |   |   | 59 |   |
| Total      liabilities                                                                                                                                                                                    |   |              | 9,638    |   |   |   | 16,691 |   |
| Commitments      and contingencies (Note 16)                                                                                                                                                              |   |              |     |   |   |   |   |   |
| Stockholders'      equity:                                                                                                                                                                                |   |              |     |   |   |   |   |   |
| Preferred      stock, $.01 par value, 5,400,000 shares authorized – Series C Junior      Participating Preferred Stock, $.01 par value, 200,000 shares authorized,      none issued and outstanding |   |              | —  |   |   |   | — |   |
| Common      stock, $.01 par value, 100,000,000 and 50,000,000 shares authorized,      35,570,836 and 29,605,631 shares issued and outstanding at December 31,      2007 and 2006, respectively            |   |              | 356      |   |   |   | 296 |   |
| Additional      paid-in capital                                                                                                                                                                           |   |              | 472,648  |   |   |   | 465,016 |   |
| Accumulated      other comprehensive income                                                                                                                                                               |   |              | 47       |   |   |   | 20 |   |
| Accumulated      deficit                                                                                                                                                                                  |   |              | (453,362 | ) |   |   | (427,670 | ) |
| Total      stockholders' equity                                                                                                                                                                           |   |              | 19,689   |   |   |   | 37,662 |   |
|                                                                                                                                                                                                      |   | $                 | 29,327   |   |   | $ | 54,353 |   |

----

Table of Contents

CYTOGEN CORPORATION AND SUBSIDIARIES

|                                                    |   | Year      Ended December 31, |    |
|---------------------------------------------------------|--------|------------------------------|---------|
|                                                    |   |                         |    |   |   |   |   |   |   |
|                                                    |   | 2007                         |    |   | 2006 |   |   | 2005 |   |
| REVENUES:                                               |   |                         |    |   |   |   |   |   |   |
| Product      revenue:                                   |   |                         |    |   |   |   |   |   |   |
| PROSTASCINT                                             |   | $                            | 9,636   |   |   | $ | 9,125 |   |   | $ | 7,407 |   |
| QUADRAMET                                               |   |                         | 9,301   |   |   |   | 8,141 |   |   |   | 8,350 |   |
| CAPHOSOL                                                |   |                         | 1,275   |   |   |   | — |   |   |   | — |   |
| Others                                                  |   |                         | — |   |   |   | 30 |   |   |   | — |   |
| Total      product revenue                              |   |                         | 20,212  |   |   |   | 17,296 |   |   |   | 15,757 |   |
| License      and contract revenue                       |   |                         | 6       |   |   |   | 11 |   |   |   | 189 |   |
|                                                    |   |                         |    |   |   |   |   |   |   |   |   |   |
| Total      revenues                                     |   |                         | 20,218  |   |   |   | 17,307 |   |   |   | 15,946 |   |
|                                                    |   |                         |    |   |   |   |   |   |   |   |   |   |
| OPERATING      EXPENSES:                                |   |                         |    |   |   |   |   |   |   |   |   |   |
| Cost      of product revenue                            |   |                         | 13,053  |   |   |   | 10,150 |   |   |   | 9,523 |   |
| Selling,      general and administrative                |   |                         | 39,086  |   |   |   | 30,166 |   |   |   | 25,895 |   |
| Research      and development                           |   |                         | 5,851   |   |   |   | 7,301 |   |   |   | 6,162 |   |
| Equity      in loss of joint venture                    |   |                         | — |   |   |   | 120 |   |   |   | 3,175 |   |
| Impairment      of intangible asset                     |   |                         | 1,767   |   |   |   | — |   |   |   | — |   |
| Total      operating expenses                           |   |                         | 59,757  |   |   |   | 47,737 |   |   |   | 44,755 |   |
| Operating      loss                                     |   |                         | (39,539 | ) |   |   | (30,430 | ) |   |   | (28,809 | ) |
| Interest      income                                    |   |                         | 1,092   |   |   |   | 1,451 |   |   |   | 712 |   |
| Interest      expense                                   |   |                         | (66     | ) |   |   | (36 | ) |   |   | (114 | ) |
| Advanced      Magnetics Inc. litigation settlement, net |   |                         | 3,946   |   |   |   | — |   |   |   | — |   |
| Gain      on sale of equity interest in joint venture   |   |                         | — |   |   |   | 12,873 |   |   |   | — |   |
| Decrease      in value of warrant liabilities           |   |                         | 8,875   |   |   |   | 1,039 |   |   |   | 1,666 |   |
| Loss      before income taxes                           |   |                         | (25,692 | ) |   |   | (15,103 | ) |   |   | (26,545 | ) |
| Income      tax benefit                                 |   |                         | — |   |   |   | — |   |   |   | (256 | ) |
| Net      loss                                           |   | $                            | (25,692 | ) |   | $ | (15,103 | ) |   | $ | (26,289 | ) |
| Basic      and diluted net loss per share               |   | $                            | (0.79   | ) |   | $ | (0.64 | ) |   | $ | (1.54 | ) |
| Weighted-average      common shares outstanding         |   |                         | 32,496  |   |   |   | 23,494 |   |   |   | 17,117 |   |

----

Table of Contents

CYTOGEN

|                                                                                      |  Common      Stock | AdditionalPaid-inCapital          | Unearned      Compensa-tion | AccumulatedOtherComprehensiveIncome                     | AccumulatedDeficit                           | TotalStockholders'Equity                      |
|-------------------------------------------------------------------------------------------|-------------------------|-----------------------------------|-----------------------------|---------------------------------------------------------|----------------------------------------------|-----------------------------------------------|
|  Share                                                                               |  Amount            |
|                                                                                      |                    |                              |                        |                                                    |                                         |                                          |   |
| Balance,      December 31, 2004                                                           | 15,489,116              | $   155            | $  426,153        | $      —            | $      — | $      (386,278)                              | $        40,030 |
|                                                                                      |                    |                              |                        |                                                    |                                         |                                          |   |
| Sale      of shares of common stock including exercise of stock options and      warrants | 6,887,847               | 69                                | 23,129                      | —                                                 | —                                      | —                                       | 23,198 |
| Issuance      of shares of common stock related to compensation                           | 4,000                   | —                           | 19                          | —                                                 | —                                      | —                                       | 19 |
| Issuance      of shares of common stock related to Prostagen                              | 92,799                  | 1                                 | 499                         | —                                                 | —                                      | —                                       | 500 |
| Unearned      compensation related to non-vested stock grants                             | —                 | —                           | 869                         | (869)                                                   | —                                      | —                                       | — |
| Reversal      of unearned compensation related to non-vested stockgrants                  | —                 | —                           | (167)                       | 167                                                     | —                                      | —                                       | — |
| Amortization      of unearned compensation                                                | —                 | —                           | —                     | 92                                                      | —                                      | —                                       | 92 |
| Comprehensive      loss:                                                                  |                    |                              |                        |                                                    |                                         |                                          |   |
| Net      loss                                                                             | —                 | —                           | —                     | —                                                 | —                                      | (26,289)                                      | (26,289) |
| Unrealized      gain on marketable securities                                             | —                 | —                           | —                     | —                                                 | 28                                           | —                                       | 28 |
| Total      comprehensive loss                                                             | —                 | —                           | —                     | —                                                 | —                                      | —                                       | (26,261) |
|                                                                                      |                    |                              |                        |                                                    |                                         |                                          |   |
| Balance,      December 31, 2005                                                           | 22,473,762              | 225                               | 450,502                     | (610)                                                   | 28                                           | (412,567)                                     | 37,578 |
|                                                                                      |                    |                              |                        |                                                    |                                         |                                          |   |
| Sale      of shares of common stock                                                       | 7,131,869               | 71                                | 13,247                      | —                                                 | —                                      | —                                       | 13,318 |
| Share-based      compensation expense                                                     | —                 | —                           | 1,877                       | —                                                 | —                                      | —                                       | 1,877 |
| Reversal      of unearned compensation related to non-vested stockgrants                  | —                 | —                           | (610)                       | 610                                                     | —                                      | —                                       | — |
| Comprehensive      loss:                                                                  |                    |                              |                        |                                                    |                                         |                                          |   |
| Net      loss                                                                             | —                 | —                           | —                     | —                                                 | —                                      | (15,103)                                      | (15,103) |
| Unrealized      loss on marketable securities                                             | —                 | —                           | —                     | —                                                 | (8)                                          | —                                       | (8) |
| Total      comprehensive loss                                                             | —                 | —                           | —                     | —                                                 | —                                      | —                                       | (15,111) |
|                                                                                      |                    |                              |                        |                                                    |                                         |                                          |   |
| Balance,      December 31, 2006                                                           | 29,605,631              |      296 |    465,016   |         — | 20                                           |       (427,670) |         37,662 |
|                                                                                      |                    |                              |                        |                                                    |                                         |                                          |   |
| Sale      of shares of common stock                                                       | 5,965,205               | 60                                | 6,559                       | —                                                 | —                                      | —                                       | 6,619 |
| Share-based      compensation expense related to warrants issued to placement      agents | —                 | —                           | (255)                       | —                                                 | —                                      | —                                       | (255) |
| Share-based      compensation expense related to grants to employees                      | —                 | —                           | 1,328                       | —                                                 | —                                      | —                                       | 1,328 |
| Comprehensive      loss:                                                                  |                    |                              |                        |                                                    |                                         |                                          |   |
|     Net      loss                                                     | —                 | —                           | —                     | —                                                 | —                                      | (25,692)                                      | (25,692) |
|     Unrealized      gain on marketable securities                     | —                 | —                           | —                     | —                                                 | 27                                           | —                                       | 27 |
| Total      comprehensive loss                                                             | —                 | —                           | —                     | —                                                 | —                                      | —                                       |       (25,665) |
|                                                                                      |                    |                              |                        |                                                    |                                         |                                          |   |
| Balance,      December 31, 2007                                                           |  35,570,836        | $   356            | $   472,648  | $      —            | $      47      | $ (453,362)                              | $        19,689 |

----

Table of Contents

CYTOGEN CORPORATION AND SUBSIDIARIES

|                                                                                  |   | Year      Ended December 31, |    |
|---------------------------------------------------------------------------------------|--------|------------------------------|---------|
|                                                                                  |   |                         |    |
|                                                                                  |   | 2007                         |    |   | 2006 |   |   | 2005 |   |
|                                                                                  |   |                         |    |   |   |   |   |   |   |
| CASH      FLOWS FROM OPERATING ACTIVITIES:                                            |   |                         |    |   |   |   |   |   |   |
| Net      loss                                                                         |   | $                            | (25,692 | ) |   | $ | (15,103 | ) |   | $ | (26,289 | ) |
| Adjustments      to reconcile net loss to net cash used in operating      activities: |   |                         |    |   |   |   |   |   |   |   |   |   |
| Depreciation      and amortization                                                    |   |                         | 1,703   |   |   |   | 1,366 |   |   |   | 1,018 |   |
| Decrease      in value of warrant liabilities                                         |   |                         | (8,875  | ) |   |   | (1,039 | ) |   |   | (1,666 | ) |
| Share-based      compensation expense                                                 |   |                         | 1,435   |   |   |   | 1,877 |   |   |   | 111 |   |
| Share-based      milestone obligation                                                 |   |                         | — |   |   |   | — |   |   |   | 500 |   |
| Increase      (decrease) in provision for doubtful accounts                           |   |                         | 13      |   |   |   | 2 |   |   |   | (72 | ) |
| Gain      on sale of equity interest in joint venture                                 |   |                         | — |   |   |   | (12,873 | ) |   |   | — |   |
| Impairment      of intangible asset                                                   |   |                         | 1,767   |   |   |   | — |   |   |   | — |   |
| Inventory      write-down                                                             |   |                         | 1,132   |   |   |   | — |   |   |   | — |   |
| Other                                                                                 |   |                         | 55      |   |   |   | (19 | ) |   |   | 64 |   |
| Changes      in assets and liabilities:                                               |   |                         |    |   |   |   |   |   |   |   |   |   |
| Accounts      receivables                                                             |   |                         | (647    | ) |   |   | (372 | ) |   |   | (265 | ) |
| Inventories                                                                           |   |                         | (3,205  | ) |   |   | 1,044 |   |   |   | 51 |   |
| Other      assets                                                                     |   |                         | 1,786   |   |   |   | (1,588 | ) |   |   | (139 | ) |
| Liability      related to joint venture                                               |   |                         | — |   |   |   | — |   |   |   | (396 | ) |
| Accounts      payable and accrued liabilities                                         |   |                         | (601    | ) |   |   | 3,852 |   |   |   | (2,385 | ) |
|                                                                                  |   |                         |    |   |   |   |   |   |   |   |   |   |
| Net      cash used in operating activities                                            |   |                         | (31,129 | ) |   |   | (22,853 | ) |   |   | (29,468 | ) |
|                                                                                  |   |                         |    |   |   |   |   |   |   |   |   |   |
| CASH      FLOWS FROM INVESTING ACTIVITIES:                                            |   |                         |    |   |   |   |   |   |   |   |   |   |
| Purchases      of product rights                                                      |   |                         | (1,200  | ) |   |   | (6,845 | ) |   |   | — |   |
| Purchases      of property and equipment                                              |   |                         | (840    | ) |   |   | (171 | ) |   |   | (405 | ) |
| Proceeds      from sale of equity interest in joint venture                           |   |                         | — |   |   |   | 13,132 |   |   |   | — |   |
| Maturities      of short-term investments                                             |   |                         | — |   |   |   | — |   |   |   | 22,727 |   |
|                                                                                  |   |                         |    |   |   |   |   |   |   |   |   |   |
| Net      cash provided by (used in) investing activities                              |   |                         | (2,040  | ) |   |   | 6,116 |   |   |   | 22,322 |   |
|                                                                                  |   |                         |    |   |   |   |   |   |   |   |   |   |
| CASH      FLOWS FROM FINANCING ACTIVITIES:                                            |   |                         |    |   |   |   |   |   |   |   |   |   |
| Proceeds      from issuance of common stock                                           |   |                         | 6,619   |   |   |   | 13,318 |   |   |   | 23,198 |   |
| Proceeds      from issuance of warrants                                               |   |                         | 3,041   |   |   |   | 5,634 |   |   |   | 3,535 |   |
| Payments      of long-term liabilities                                                |   |                         | (84     | ) |   |   | (45 | ) |   |   | (2,296 | ) |
|                                                                                  |   |                         |    |   |   |   |   |   |   |   |   |   |
| Net      cash provided by financing activities                                        |   |                         | 9,576   |   |   |   | 18,907 |   |   |   | 24,437 |   |
|                                                                                  |   |                         |    |   |   |   |   |   |   |   |   |   |
| Net      increase (decrease) in cash and cash equivalents                             |   |                         | (23,593 | ) |   |   | 2,170 |   |   |   | 17,291 |   |
| Cash      and cash equivalents, beginning of year                                     |   |                         | 32,507  |   |   |   | 30,337 |   |   |   | 13,046 |   |
|                                                                                  |   |                         |    |   |   |   |   |   |   |   |   |   |
| Cash      and cash equivalents, end of year                                           |   | $                            | 8,914   |   |   | $ | 32,507 |   |   | $ | 30,337 |   |
| Supplemental      disclosure of non-cash information:                                 |   |                         |    |   |   |   |   |   |   |   |   |   |
| Unrealized      holding gain (loss) on marketable securities                          |   | $                            | 27      |   |   | $ | (8 | ) |   | $ | 28 |   |
| Capital      lease of equipment                                                       |   |                         | 113     |   |   |   | 96 |   |   |   | 25 |   |
| Issuance      of warrants to placement agents                                         |   |                         | 365     |   |   |   | — |   |   |   | — |   |
| Share-based      compensation charged to inventory                                    |   |                         | 3       |   |   |   | — |   |   |   | — |   |
| Supplemental      disclosure of cash information:                                     |   |                         |    |   |   |   |   |   |   |   |   |   |
| Cash      paid for interest                                                           |   | $                            | 36      |   |   | $ | 32 |   |   | $ | 395 |   |
| Cash      received for taxes                                                          |   |                         | — |   |   |   | — |   |   |   | 256 |   |

----

Table of Contents

CYTOGEN

| 1. | SUMMARY      OF SIGNIFICANT ACCOUNTING POLICIES |
|----|-------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                                                                                                                                                                                                                                                                               |   | December      31,               |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|--------|
|                                                                                                                                                                                                                                                                                               |   | 2007                            |   |   | 2006 |   |
|                                                                                                                                                                                                                                                                                               |   | (All      amounts in thousands) |   |
| Raw      materials                                                |   | $                               | 82     |   |   | $ | 325 |   |
| Work-in      process                                              |   |                            | 3,221  |   |   |   | 1,296 |   |
| Finished      goods                                               |   |                            | 1,332  |   |   |   | 917 |   |
|                                                                                                                                                                                                                                                                                               |   |                            |   |   |   |   |   |   |
|                                                                                                                                                                                                                                                                                               |   | $                               | 4,635  |   |   | $ | 2,538 |   |

----

Table of Contents

|                                                 |   | December      31,               |   |
|------------------------------------------------------|--------|---------------------------------|--------|
|                                                 |   | 2007                            |   |   | 2006 |   |
|                                                 |   | (All      amounts in thousands) |   |
| Leasehold      improvements                          |   | $                               | 181    |   |   | $ | 175 |   |
| Equipment      and furniture                         |   |                            | 2,527  |   |   |   | 1,925 |   |
|                                                 |   |                            | 2,708  |   |   |   | 2,100 |   |
| Less:      Accumulated depreciation and amortization |   |                            | (1,662 | ) |   |   | (1,409 | ) |
|                                                 |   | $                               | 1,046  |   |   | $ | 691 |   |

----

Table of Contents

|                                         |   | December      31,               |    |
|----------------------------------------------|--------|---------------------------------|---------|
|                                         |   | 2007                            |    |   | 2006 |   |
|                                         |   | (All      amounts in thousands) |    |
| QUADRAMET      license fee, net (see Note 6) |   | $                               | 4,934   |   |   | $ | 5,631 |   |
| SOLTAMOX      license fee, net (see Note 17) |   |                            | — |   |   |   | 1,890 |   |
| CAPHOSOL      license fee, net (see Note 19) |   |                            | 3,908   |   |   |   | 4,091 |   |
|                                         |   | $                               | 8,842   |   |   | $ | 11,612 |   |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | December      31,               |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|--------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | 2007                            |   |   | 2006 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | (All      amounts in thousands) |   |
| QUADRAMET      license      fee                                                                                       |   | $                               | 8,000  |   |   | $ | 8,000 |   |
| Less:      Accumulated      amortization                                                                              |   |                            | (3,066 | ) |   |   | (2,369 | ) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | $                               | 4,934  |   |   | $ | 5,631 |   |

----

Table of Contents

|                                      |   | December      31,               |    |
|-------------------------------------------|--------|---------------------------------|---------|
|                                      |   | 2007                            |    |   | 2006 |   |
|                                      |   | (All      amounts in thousands) |    |
| SOLTAMOX      license fee                 |   | $                               | 2,000   |   |   | $ | 2,000 |   |
| Less:      Accumulated amortization       |   |                            | (233    | ) |   |   | (110 | ) |
| Less:      Impairment of intangible asset |   |                            | (1,767  | ) |   |   | — |   |
|                                      |   | $                               | — |   |   | $ | 1,890 |   |

|                                    |   | December      31,               |   |
|-----------------------------------------|--------|---------------------------------|--------|
|                                    |   | 2007                            |   |   | 2006 |   |
|                                    |   | (All      amounts in thousands) |   |
| CAPHOSOL      license fee               |   | $                               | 4,189  |   |   | $ | 4,189 |   |
| Add:  Contingent      payment |   |                            | 200    |   |   |   | — |   |
| Less:      Accumulated amortization     |   |                            | (481   | ) |   |   | (98 | ) |
|                                    |   | $                               | 3,908  |   |   | $ | 4,091 |   |

----

Table of Contents

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | December      31,               |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|---------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | 2007                            |    |   | 2006 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | (All      amounts in thousands) |    |
| CAPHOSOL      option fee for      Europe                                                                              |   | $                               | 1,656   |   |   | $ | 1,656 |   |
| Deferred      royalty      expense                                                                                    |   |                            | — |   |   |   | 105 |   |
| Other                                                                                                                 |   |                            | 296     |   |   |   | 304 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | $                               | 1,952   |   |   | $ | 2,065 |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| 2. | ADVANCED      MAGNETICS, INC. |
|----|-------------------------------|

----

Table of Contents

| 4. | PSMA      DEVELOPMENT COMPANY LLC |
|----|-----------------------------------|

----

Table of Contents

|                                                                                                                                                                                                                 |   | From      January 1, 2006 to April 20, 2006 |   |   | Year      EndedDecember      31, 2005 |   |   | For      the Period From June 15, 1999 (inception) to April 20,      2006 |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------|--------|--------|---------------------------------------|--------|--------|---------------------------------------------------------------------------|--------|
|                                                                                                                                                                                                                 |   |                                        |   |   |                                  |   |   |                                                                      |   |
| Interest      income                                 |   | $                                           | 6      |   |                                  | $      | 9      |                                                                      |   | $ | 256 |   |
| Total      expenses                                                                                                                                                                                                  |   |                                        | 246    |   |                                  |   | 6,358  |                                                                      |   |   | 30,953 |   |
|                                                                                                                                                                                                                 |   |                                        |   |   |                                  |   |   |                                                                      |   |   |   |   |
| Net      loss                                        |   | $                                           | (240   | )      |                                  | $      | (6,349 | )                                                                         |   | $ | (30,697 | ) |

| 5. | THE      DOW CHEMICAL COMPANY |
|----|-------------------------------|

----

Table of Contents

| 6. | BERLEX      LABORATORIES INC. |
|----|-------------------------------|

| 7. | BRISTOL-MYERS      SQUIBB MEDICAL IMAGING, INC. |
|----|-------------------------------------------------|

----

Table of Contents

----

Table of Contents

| 9. | REVENUES      FROM MAJOR CUSTOMERS |
|----|------------------------------------|

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   | Year      Ended December 31, |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------|--------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   | 2007                         |   |   | 2006 |   |   | 2005 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   |                         |   |   |   |   |   |   |   |
| Cardinal      Health                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   |                         | 43     | % |   |   | 41 | % |   |   | 47 | % |
| Mallinckrodt      Inc.                                                                                  |   |                         | 14     | % |   |   | 14 | % |   |   | 11 | % |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   | December      31,               |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|---------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   | 2007                            |    |   | 2006 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   |                            |    |   |   |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   | (All      amounts in thousands) |    |
| Accounts      payable                                                                                                                   |   | $                               | 3,110   |   |   | $ | 2,199 |   |
| Accrued      payroll, sales commission and related expenses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   |                            | 1,340   |   |   |   | 1,766 |   |
| Accrued      royalty      expense                                                                                                       |   |                            | 1,019   |   |   |   | 909 |   |
| Accrued      professional and legal      expenses                                                                                       |   |                            | 620     |   |   |   | 806 |   |
| Accrued      research contracts and      materials                                                                                      |   |                            | 331     |   |   |   | 467 |   |
| Accrued      manufacturing      costs                                                                                                   |   |                            | 227     |   |   |   | 170 |   |
| Accrued      marketing      expenses                                                                                                    |   |                            | 992     |   |   |   | 1,545 |   |
| Liability      to InPharma (see Note      19)                                                                                           |   |                            | — |   |   |   | 1,000 |   |
| Insurance      liability                                                                                                                |   |                            | 330     |   |   |   | 338 |   |
| Other      accruals                                                                                                                     |   |                            | 521     |   |   |   | 904 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   | $                               | 8,490   |   |   | $ | 10,104 |   |

----

Table of Contents

| 11. | LONG-TERM      LIABILITIES |
|-----|----------------------------|

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | December      31,               |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|--------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | 2007                            |   |   | 2006 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | (All      amounts in thousands) |   |
| Capital      lease      obligations                                                                                |   | $                               | 153    |   |   | $ | 123 |   |
| Warrant      liabilities                                                                                           |   |                            | 995    |   |   |   | 6,464 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |                            | 1,148  |   |   |   | 6,587 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |                            |   |   |   |   |   |   |
| Less:      Current portion of long-term liabilities                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |   |                            | (87    | ) |   |   | (64 | ) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | $                               | 1,061  |   |   | $ | 6,523 |   |

----

Table of Contents

|                            |   | July      20,2005 |   |   | August      2,2005 |   |   | December      31, 2005 |   |   | December      31, 2006 |   |   | December      31, 2007 |   |
|---------------------------------|--------|-------------------|--------|--------|--------------------|--------|--------|------------------------|--------|--------|------------------------|--------|--------|------------------------|--------|
| Dividend      yield             |   |              | 0      | %      |               |   | 0      | %                      |   |   | 0                      | %      |   |                   | 0      | % |   |   | 0 | % |
| Expected      volatility        |   |              | 105.27 | %      |               |   | 105.03 | %                      |   |   | 105.86                 | %      |   |                   | 104.00 | % |   |   | 89.02 | % |
| Expected      life              |   | 10.0      years   |   |   | 10.0      years    |   |   | 9.6      years         |   |   | 8.6      years         |   |   | 7.6      years         |   |
| Risk-free      interest rate    |   |              | 4.25   | %      |               |   | 4.41   | %                      |   |   | 4.40                   | %      |   |                   | 4.77   | % |   |   | 4.00 | % |
| Company      Common Stock Price |   | $                 | 4.92   |   |               | $      | 5.04   |                   |   | $      | 2.74                   |   |   | $                      | 2.33   |   |   | $ | 0.53 |   |

|                            |   | November      10, 2006 |   |   | December      31,2006 |   |   | December      31,2007 |   |
|---------------------------------|--------|------------------------|--------|--------|-----------------------|--------|--------|-----------------------|--------|
| Dividend      yield             |   |                   | 0      | %      |                  |   | 0      | %                     |   |   | 0 | % |
| Expected      volatility        |   |                   | 81.11  | %      |                  |   | 80.15  | %                     |   |   | 69.77 | % |
| Expected      life              |   | 5.0      years         |   |   | 4.9      years        |   |   | 3.9      years        |   |
| Risk-free      interest rate    |   |                   | 4.61   | %      |                  |   | 4.74   | %                     |   |   | 3.33 | % |
| Company      Common Stock Price |   | $                      | 2.53   |   |                  | $      | 2.33   |                  |   | $ | 0.53 |   |

----

Table of Contents

|                            |   | July      6,2007 |   |   | December      31, 2007 |   |
|---------------------------------|--------|------------------|--------|--------|------------------------|--------|
| Dividend      yield             |   |             | 0      | %      |                   |   | 0 | % |
| Expected      volatility        |   |             | 78.56  | %      |                   |   | 71.74 | % |
| Expected      life              |   | 5.5      years   |   |   | 5.0      years         |   |
| Risk-free      interest rate    |   |             | 5.17   | %      |                   |   | 3.49 | % |
| Company      Common Stock Price |   | $                | 1.64   |   |                   | $      | 0.53 |   |

----

Table of Contents

| 12. | PREFERRED      STOCK, COMMON STOCK AND WARRANTS |
|-----|-------------------------------------------------|

----

Table of Contents

----

Table of Contents

|                                                                                                                                                                                                                                                      |   | Number      ofWarrants |       |   | Price      RangePer      Share |   |                    | Weighted-Average      Exercise Price Per Share |   |   | Aggregate      ExercisePrice |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------|------------|--------|--------------------------------|--------|-------------------------|------------------------------------------------|--------|--------|------------------------------|--------|
| Balance      at December 31, 2004                                                                                                                                                                                                                         |   |                   | 1,938,122  |   |                           | $      | 5.65      - $12.80      |                                           |   | $      | 11.24                        |   |   | $ | 21,775,459 |   |
| Granted                                           |   |                   | 1,894,964  |   |                           |   | 4.25      – 6.00  |                                           |   |   | 4.97                         |   |   |   | 9,411,765 |   |
| Exercised                                         |   |                   | (30,000    | )      |                           |   | 5.65                    |                                           |   |   | 5.65                         |   |   |   | (169,500 | ) |
| Expired                                           |   |                   | —    |   |                           |   | —                 |                                           |   |   | —                      |   |   |   | — |   |
|                                                                                                                                                                                                                                                      |   |                   |       |   |                           |   |                    |                                           |   |   |                         |   |   |   |   |   |
| Balance      at December 31, 2005                                                                                                                                                                                                                         |   |                   | 3,803,086  |   |                           |   | 4.25      – 12.80 |                                           |   |   | 8.16                         |   |   |   | 31,017,724 |   |
| Granted                                           |   |                   | 3,546,107  |   |                           |   | 3.32                    |                                           |   |   | 3.32                         |   |   |   | 11,773,075 |   |
| Exercised                                         |   |                   | —    |   |                           |   | —                 |                                           |   |   | —                      |   |   |   | — |   |
| Expired                                           |   |                   | (70,000    | )      |                           |   | 5.65                    |                                           |   |   | 5.65                         |   |   |   | (395,500 | ) |
|                                                                                                                                                                                                                                                      |   |                   |       |   |                           |   |                    |                                           |   |   |                         |   |   |   |   |   |
| Balance      at December 31, 2006                                                                                                                                                                                                                         |   |                   | 7,279,193  |   |                           |   | 3.32      – 12.80 |                                           |   |   | 5.82                         |   |   |   | 42,395,299 |   |
| Granted                                           |   |                   | 3,256,177  |   |                           |   | 2.23                    |                                           |   |   | 2.23                         |   |   |   | 7,264,531 |   |
| Exercised                                         |   |                   | —    |   |                           |   | —                 |                                           |   |   | —                      |   |   |   | — |   |
| Expired                                           |   |                   | —    |   |                           |   | —                 |                                           |   |   | —                      |   |   |   | — |   |
|                                                                                                                                                                                                                                                      |   |                   |       |   |                           |   |                    |                                           |   |   |                         |   |   |   |   |   |
| Balance      at December 31, 2007                                                                                                                                                                                                                         |   |                   | 10,535,370 |   |                           | $      | 2.23      - $12.80      |                                           |   | $      | 4.71                         |   |   | $ | 49,659,830 |   |

| Exercise      Price |   |   | Outstanding      Warrants |   |      | Aggregate      Exercise Price |   |
|---------------------|--------|--------|---------------------------|--------|-----------|-------------------------------|--------|
| $                   | 2.23   |   |                      |   | 3,256,177 |                          |   | $ | 7,264,532 |   |
| $                   | 3.32   |   |                      |   | 3,546,107 |                          |   | $ | 11,773,075 |   |
| $                   | 4.25   |   |                      |   | 1,118,868 |                          |   | $ | 4,755,189 |   |
| $                   | 6.00   |   |                      |   | 776,096   |                          |   | $ | 4,656,576 |   |
| $                   | 6.91   |   |                      |   | 315,790   |                          |   | $ | 2,182,108 |   |
| $                   | 10.97  |   |                      |   | 250,000   |                          |   | $ | 2,742,500 |   |
| $                   | 12.80  |   |                      |   | 1,272,332 |                          |   | $ | 16,285,850 |   |

----

Table of Contents

| 13. | SHARE-BASED      COMPENSATION |
|-----|-------------------------------|

----

Table of Contents

----

Table of Contents

| Cytogen      Options Other      than Performance      Options                                                                                                                                                                                                          |   | Number      ofCytogenStockOptions |      |   | Weighted-AverageExercisePrice      PerShare |   |    | Weighted-Average      Remaining Contractual Life |   |   | Aggregate      Intrinsic Value |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------|-----------|--------|---------------------------------------------|--------|---------|--------------------------------------------------|--------|--------|--------------------------------|--------|
| Balance      at December 31, 2006                                                                                                                                                                                                                                           |   |                              | 1,460,519 |   |                                        | $      | 7.14    |                                             |   |   | 8.12                           |   |   | $ | 4,000 |   |
| Granted                                              |   |                              | 1,394,500 |   |                                        |   | 1.71    |                                             |   |   |                           |   |   |   |   |   |
| Exercised                                            |   |                              | —   |   |                                        |   | — |                                             |   |   |                           |   |   |   |   |   |
| Forfeited                                            |   |                              | (519,330  | )      |                                        |   | 2.95    |                                             |   |   |                           |   |   |   |   |   |
| Expired                                              |   |                              | (63,762   | )      |                                        |   | 8.90    |                                             |   |   |                           |   |   |   |   |   |
|                                                                                                                                                                                                                                                                        |   |                              |      |   |                                        |   |    |                                             |   |   |                           |   |   |   |   |   |
| Balance      at December 31, 2007                                                                                                                                                                                                                                           |   |                              | 2,271,927 |   |                                        | $      | 4.71    |                                             |   |   | 7.45                           |   |   | $ | — |   |
|                                                                                                                                                                                                                                                                        |   |                              |      |   |                                        |   |    |                                             |   |   |                           |   |   |   |   |   |
| Exercisable      and expected to vest at December 31, 2007                                                                                                                                                                                                                  |   |                              | 1,941,012 |   |                                        | $      | 5.12    |                                             |   |   | 8.06                           |   |   | $ | — |   |
|                                                                                                                                                                                                                                                                        |   |                              |      |   |                                        |   |    |                                             |   |   |                           |   |   |   |   |   |
| Exercisable      at December 31, 2007                                                                                                                                                                                                                                       |   |                              | 961,769   |   |                                        | $      | 8.63    |                                             |   |   | 4.90                           |   |   | $ | — |   |
|                                                                                                                                                                                                                                                                        |   |                              |      |   |                                        |   |    |                                             |   |   |                           |   |   |   |   |   |

----

Table of Contents

| Performance      Options                                                                                                                                                                                                                                                          |   | Number      of Cytogen Stock Options |     |   | Weighted-Average      Exercise Price Per Share |   |    | Weighted-Average      Remaining Contractual Life |   |   | Aggregate      Intrinsic Value |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------|----------|--------|------------------------------------------------|--------|---------|--------------------------------------------------|--------|--------|--------------------------------|--------|
| Balance      at December 31, 2006                                                                                                                                                                                                                                                 |   |                                 | 150,000  |   |                                           | $      | 3.54    |                                             |   |   | 5.97                           |   |   |   | — |   |
| Granted                                               |   |                                 | —  |   |                                           |   | — |                                             |   |   |                           |   |   |   |   |   |
| Exercised                                             |   |                                 | —  |   |                                           |   | — |                                             |   |   |                           |   |   |   |   |   |
| Forfeited                                             |   |                                 | (100,000 | )      |                                           |   | 3.54    |                                             |   |   |                           |   |   |   |   |   |
| Expired                                               |   |                                 | —  |   |                                           |   | — |                                             |   |   |                           |   |   |   |   |   |
|                                                                                                                                                                                                                                                                              |   |                                 |     |   |                                           |   |    |                                             |   |   |                           |   |   |   |   |   |
| Balance      at December 31, 2007                                                                                                                                                                                                                                                 |   |                                 | 50,000   |   |                                           | $      | 3.54    |                                             |   |   | 0.14                           |   |   |   | -- |   |
|                                                                                                                                                                                                                                                                              |   |                                 |     |   |                                           |   |    |                                             |   |   |                           |   |   |   |   |   |
| Exercisable      and expected to vest at December 31, 2007                                                                                                                                                                                                                        |   |                                 | 50,000   |   |                                           | $      | 3.54    |                                             |   |   | 0.14                           |   |   |   | -- |   |
|                                                                                                                                                                                                                                                                              |   |                                 |     |   |                                           |   |    |                                             |   |   |                           |   |   |   |   |   |
| Exercisable      at December 31, 2007                                                                                                                                                                                                                                             |   |                                 | 50,000   |   |                                           | $      | 3.54    |                                             |   |   | 0.14                           |   |   |   | -- |   |

----

Table of Contents

| Nonvested      Shares                                                                                                                                                                                                                                                                   |   | Number      ofNonvestedShares |     |   | Weighted-Average      Grant DateFair      Value |   |    | Weighted-Average      Remaining Vesting Term |   |   | Aggregate      Intrinsic Value |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------|----------|--------|-------------------------------------------------|--------|---------|----------------------------------------------|--------|--------|--------------------------------|--------|
| Balance      at December 31, 2006                                                                                                                                                                                                                                                       |   |                          | 343,900  |   |                                            | $      | 3.65    |                                         |   |   | 2.56                           |   |   | $ | 801,000 |   |
| Granted                                                |   |                          | 615,877  |   |                                            |   | 0.95    |                                         |   |   |                           |   |   |   |   |   |
| Vested                                                 |   |                          | (22,165  | )      |                                            |   | 3.47    |                                         |   |   |                           |   |   |   |   |   |
| Forfeited                                              |   |                          | (234,334 | )      |                                            |   | 3.33    |                                         |   |   |                           |   |   |   |   |   |
|                                                                                                                                                                                                                                                                                    |   |                          |     |   |                                            |   |    |                                         |   |   |                           |   |   |   |   |   |
| Balance      at December 31, 2007                                                                                                                                                                                                                                                       |   |                          | 703,278  |   |                                            | $      | 1.39    |                                         |   |   | 5.72                           |   |   | $ | 373,000 |   |
|                                                                                                                                                                                                                                                                                    |   |                          |     |   |                                            |   |    |                                         |   |   |                           |   |   |   |   |   |
| Vested      and expected to vest at December 31, 2007                                                                                                                                                                                                                                   |   |                          | 269,534  |   |                                            | $      | 2.73    |                                         |   |   | 1.47                           |   |   | $ | 143,000 |   |
|                                                                                                                                                                                                                                                                                    |   |                          |     |   |                                            |   |    |                                         |   |   |                           |   |   |   |   |   |
| Vested      at December 31, 2007                                                                                                                                                                                                                                                        |   |                          | —  |   |                                            |   | — |                                         |   |   | —                        |   |   |   | — |   |

----

Table of Contents

| Warrants      and Options to Non-Employees                                                                                                                                                                                                                                                                                  |   | Number      of Cytogen Warrants and Options |    |   | Weighted-Average      Exercise Price Per Share |   |    | Weighted-Average      Remaining Contractual Life |   |   | Aggregate      Intrinsic Value |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------|---------|--------|------------------------------------------------|--------|---------|--------------------------------------------------|--------|--------|--------------------------------|--------|
| Balance      at December 31, 2006                                                                                                                                                                                                                                                                                           |   |                                        | 289,978 |   |                                           | $      | 7.27    |                                             |   |   | 3.09                           |   |   |   | — |   |
| Granted                                                      |   |                                        | 348,876 |   |                                           |   | 2.23    |                                             |   |   |                           |   |   |   |   |   |
| Exercised                                                    |   |                                        | — |   |                                           |   | — |                                             |   |   |                           |   |   |   |   |   |
| Forfeited                                                    |   |                                        | — |   |                                           |   | — |                                             |   |   |                           |   |   |   |   |   |
| Expired                                                      |   |                                        | — |   |                                           |   | — |                                             |   |   |                           |   |   |   |   |   |
|                                                                                                                                                                                                                                                                                                                        |   |                                        |    |   |                                           |   |    |                                             |   |   |                           |   |   |   |   |   |
| Balance      at December 31, 2007                                                                                                                                                                                                                                                                                           |   |                                        | 638,854 |   |                                           | $      | 4.52    |                                             |   |   | 3.68                           |   |   |   | — |   |
|                                                                                                                                                                                                                                                                                                                        |   |                                        |    |   |                                           |   |    |                                             |   |   |                           |   |   |   |   |   |
| Exercisable      and expected to vest at December 31, 2007                                                                                                                                                                                                                                                                  |   |                                        | 638,854 |   |                                           | $      | 4.52    |                                             |   |   | 3.68                           |   |   |   | — |   |
|                                                                                                                                                                                                                                                                                                                        |   |                                        |    |   |                                           |   |    |                                             |   |   |                           |   |   |   |   |   |
| Exercisable      at December 31, 2007                                                                                                                                                                                                                                                                                       |   |                                        | 638,854 |   |                                           | $      | 4.52    |                                             |   |   | 3.68                           |   |   |   | — |   |

----

Table of Contents

|  AxCell      Stock Options                                                                                                                                                                                                                                                                                                                           |   | Number      of AxCell StockOptions |    |   | Weighted-Average      Exercise Price |   |    | Weighted-Average      Remaining Contractual Term |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------|---------|--------|--------------------------------------|--------|---------|--------------------------------------------------|--------|
| Balance      at December 31, 2006                                                                                                                                                                                                                                                                                                                         |   |                               | 50,000  |   |                                 | $      | 4.63    |                                             |   |   | 5.33 |   |
| Granted                                                           |   |                               | — |   |                                 |   | — |                                             |   |   |   |   |
| Exercised                                                         |   |                               | — |   |                                 |   | — |                                             |   |   |   |   |
| Forfeited                                                         |   |                               | — |   |                                 |   | — |                                             |   |   |   |   |
| Expired                                                           |   |                               | — |   |                                 |   | — |                                             |   |   |   |   |
|                                                                                                                                                                                                                                                                                                                                                      |   |                               |    |   |                                 |   |    |                                             |   |   |   |   |
| Balance      at December 31, 2007                                                                                                                                                                                                                                                                                                                         |   |                               | 50,000  |   |                                 | $      | 4.63    |                                             |   |   | 0.14 |   |
|                                                                                                                                                                                                                                                                                                                                                      |   |                               |    |   |                                 |   |    |                                             |   |   |   |   |
| Exercisable      and expected to vest at December 31, 2007                                                                                                                                                                                                                                                                                                |   |                               | 50,000  |   |                                 | $      | 4.63    |                                             |   |   | 0.14 |   |
|                                                                                                                                                                                                                                                                                                                                                      |   |                               |    |   |                                 |   |    |                                             |   |   |   |   |
| Exercisable      at December 31, 2007                                                                                                                                                                                                                                                                                                                     |   |                               | 50,000  |   |                                 | $      | 4.63    |                                             |   |   | 0.14 |   |

----

Table of Contents

|                                                                                                                                                                                                                                                                                                                                                                                                                            |   | Year      EndedDecember      31, |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                            |   | 2005                             |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                            |   |                             |   |
| Net      loss, as      reported                                                                 |   | $                                | (26,289 | ) |
| Add:      Stock-based employee compensation expense included in reported net      loss                                                                                                                                                                                                                                                                                                                                          |   |                             | 111 |   |
| Deduct:      Total stock-based employee compensation expense determined under fair      value-based method for all awards                                                                                                                                                                                                                                                                                                       |   |                             | (1,894 | ) |
| Pro      forma net      loss                                                                    |   | $                                | (28,072 | ) |
| Basic      and diluted net loss per share, as reported                                                                                                                                                                                                                                                                                                                                                                          |   | $                                | (1.54 | ) |
| Pro      forma basic and diluted net loss per share                                                                                                                                                                                                                                                                                                                                                                             |   | $                                | (1.64 | ) |

|                                     |   | Year      EndedDecember      31, |   |
|------------------------------------------|--------|----------------------------------|--------|
|                                     |   | 2007                             |   |   | 2006 |   |
|                                     |   |                             |   |   |   |   |
| Selling,      general and administrative |   | $                                | 1,134  |   |   | $ | 1,625 |   |
| Research      and development            |   |                             | 191    |   |   |   | 252 |   |
|                                     |   | $                                | 1,325  |   |   | $ | 1,877 |   |

----

Table of Contents

| Valuation      Assumptions                                                                                                                                                                                                                                                                                                                                                                                |   | 2007         |   |   | 2006         |   |   | 2005         |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|--------|--------|--------------|--------|--------|--------------|--------|
| Dividend      yield                                                                           |   |         | 0      | %      |         |   | 0      | %            |   |   | 0 | % |
| Expected      volatility                                                                      |   |         | 83     | %      |         |   | 96     | %            |   |   | 96 | % |
| Risk-free      interest      rate                                                             |   |         | 4.51   | %      |         |   | 4.88   | %            |   |   | 3.97 | % |
| Expected      life                                                                            |   | 6.2      yrs |   |   | 6.4      yrs |   |   | 4.6      yrs |   |

| Valuation      Assumptions                                                                                                                                                                                                                                                                                                                                                                                |   | 2007          |   |   | 2006          |   |   | 2005          |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|--------|---------------|--------|--------|---------------|--------|
| Dividend      yield                                                                           |   |          | 0      | %      |          |   | 0      | %             |   |   | 0 | % |
| Expected      volatility                                                                      |   |          | 73     | %      |          |   | 44     | %             |   |   | 112 | % |
| Risk-free      interest      rate                                                             |   |          | 4.46   | %      |          |   | 4.91   | %             |   |   | 2.71 | % |
| Expected      life                                                                            |   | 3      months |   |   | 2      months |   |   | 3      months |   |

----

Table of Contents

| Valuation      Assumptions                                                                                                                                                                                                                                                                                                                                                                                |   | 2007         |   |   | 2005       |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|--------|--------|------------|--------|
| Dividend      yield                                                                           |   |         | 0      | %      |       |   | 0 | % |
| Expected      volatility                                                                      |   |         | 79     | %      |       |   | 93 | % |
| Risk-free      interest      rate                                                             |   |         | 5.17   | %      |       |   | 4.43 | % |
| Expected      life                                                                            |   | 5.5      yrs |   |   | 5      yrs |   |

----

Table of Contents

| 14. | RETIREMENT      SAVINGS PLAN |
|-----|------------------------------|

| 15. | INCOME      TAXES |
|-----|-------------------|

----

Table of Contents

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |   | 2007                            |     |   | 2006   |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|----------|--------|--------|--------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |   | (All      amounts in thousands) |     |
| Deferred      tax assets:                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |                            |     |   |   |   |
| Net      operating loss carryforwards                                                                                                                                                                                                                                                                                                                                                                                                                                      |   | $                               | 123,391  |   |   | $      | 117,533 |   |
| Capitalized      research and development expenses                                                                                                                                                                                                                                                                                                                                                                                                                         |   |                            | 1,227    |   |   |   | 1,461 |   |
| Research      and development and state tax   Credits                                                                  |   |                            | 4,278    |   |   |   | 5,023 |   |
| Acquisition      of in-process technology                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |                            | 493      |   |   |   | 613 |   |
| Other,      net                                                                                                                       |   |                            | 2,259    |   |   |   | 7,040 |   |
| Total      deferred tax      assets                                                                                                                  |   |                            | 131,648  |   |   |   | 131,670 |   |
| Valuation      allowance                                                                                                                             |   |                            | (126,841 | )      |   |   | (131,670 | ) |
| Net      deferred tax      assets                                                                                                                                   |   |                            | 4,807    |   |   |   | — |   |
| Deferred      tax liabilities:                                                                                                                                                                                                                                                                                                                                                                                                                                             |   |                            |     |   |   |   |   |   |
| Other                                                                                                                                 |   |                            | (4,807   | )      |   |   | — |   |
| Net      deferred tax      assets                                                                                                                                   |   | $                               | —  |   |   | $      | — |   |

|                                                                                                                                                                                                                                                                                                                                                                    |   | 2007   |    |   | 2006   |   |    | 2005 |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|---------|--------|--------|--------|---------|------|--------|
|                                                                                                                                                                                                                                                                                                                                                                    |   |   |    |
| Federal      statutory income tax rate                                                                                                                                                                                                                                                                                                                                  |   |   | 34.0    | %      |   |   | 34.0    | %    |   |   | 34.0 | % |
| Increase      in valuation allowance                                                                                                                                                                                                                                                                                                                                    |   |   | (23.0   | %)     |   |   | (29.4   | %)   |   |   | (29.9 | %) |
| Sale      of New Jersey net operating loss carryforwards                                                                                                                                                                                                                                                                                                                |   |   | — | %      |   |   | — | %    |   |   | 1.0 | % |
| Other                                                            |   |   | (11.0   | %)     |   |   | (4.6    | %)   |   |   | (4.1 | %) |
| Effective income tax      rate                                                                      |   |   | — | %      |   |   | — | %    |   |   | 1.0 | % |

----

Table of Contents

| 16. | COMMITMENTS      AND CONTINGENCIES |
|-----|------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| 20. | LITIGATION      AND RELATED MATTERS |
|-----|-------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| 22. | CONSOLIDATED      QUARTERLY FINANCIAL DATA -UNAUDITED |
|-----|-------------------------------------------------------|

|                                                                                                                                                                                                                                                                                                                                                                                                                                                           |   | Three      Months Ended                           |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|---------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                           |   | March      31,2007                                |    |   | June      30,2007 |   |   | Sept.      30,2007 |   |   | Dec.      31,2007 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                           |   |                                              |    |   |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                           |   | (amounts      in thousands except per share data) |    |
| Total      revenues                                                                                                  |   | $                                                 | 4,808   |   |   | $ | 5,154 |   |   | $ | 5,122 |   |   | $ |  5,134 |   |
| Total      operating      expenses                                                                                   |   |                                              | 15,047  |   |   |   | 16,831 |   |   |   | 16,037 |   |   |   | 11,842 |   |
| Operating      loss                                                                                                                           |   |                                              | (10,239 | ) |   |   | (11,677 | ) |   |   | (10,915 | ) |   |   | (6,708 | ) |
| Decrease      in value of warrant      liabilities                                                                   |   |                                              | 1,095   |   |   |   | 1,020 |   |   |   | 5,536 |   |   |   | 1,224 |   |
| Advanced      Magnetics Inc. litigation settlement, net                                                                                                                                                                                                                                                                                                                                                                                                        |   |                                              | 3,946   |   |   |   | — |   |   |   | — |   |   |   | — |   |
| Other      income,      net                                                                                          |   |                                              | 366     |   |   |   | 261 |   |   |   | 260 |   |   |   | 139 |   |
| Net      loss                                                                                                        |   | $                                                 | (4,832  | ) |   | $ | (10,396 | ) |   | $ | (5,119 | ) |   | $ | (5,345 | ) |
| Basic      and diluted net loss per      share                                                                       |   | $                                                 | (0.16   | ) |   | $ | (0.35 | ) |   | $ | (0.15 | ) |   | $ | (0.15 | ) |
| Weighted-average      common shares outstanding,      basic and diluted                                                                                                                                                                                                                                                                                                                                                                                        |   |                                              | 29,606  |   |   |   | 29,644 |   |   |   | 35,099 |   |   |   | 35,513 |   |
| Product      related gross      margin                                                                               |   | $                                                 | 1,904   |   |   | $ | 1,995 |   |   | $ |  1,946 |   |   | $ | 1,314 |   |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | Three      Months Ended                           |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|---------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | March      31,2006                                |    |   | June      30,2006 |   |   | Sept.      30,2006 |   |   | Dec.      31,2006 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |                                              |    |   |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | (amounts      in thousands except per share data) |    |
| Total      revenues                                                                                       |   | $                                                 | 4,442   |   |   | $ | 4,172 |   |   | $ | 4,172 |   |   | $ | 4,521 |   |
| Total      operating      expenses                                                                        |   |                                              | 11,768  |   |   |   | 11,038 |   |   |   | 10,408 |   |   |   | 14,523 |   |
| Operating      loss                                                                                                                |   |                                              | (7,326  | ) |   |   | (6,866 | ) |   |   | (6,236 | ) |   |   | (10,002 | ) |
| Gain      on sale of equity interest in joint venture                                                                                                                                                                                                                                                                                                                                                                                                         |   |                                              | — |   |   |   | 12,873 |   |   |   | — |   |   |   | — |   |
| (Increase)      decrease in value of warrant liabilities                                                                                                                                                                                                                                                                                                                                                                                                      |   |                                              | (631    | ) |   |   | 813 |   |   |   | 122 |   |   |   | 735 |   |
| Other      (expense) income,      net                                                                     |   |                                              | 291     |   |   |   | 386 |   |   |   | 376 |   |   |   | 362 |   |
| Net      income      (loss)                                                                               |   | $                                                 | (7,666  | ) |   | $ | 7,206 |   |   | $ | (5,738 | ) |   | $ | (8,905 | ) |
| Basic      and diluted net income (loss) per share                                                                                                                                                                                                                                                                                                                                                                                                            |   | $                                                 | (0.34   | ) |   | $ | 0.32 |   |   | $ | (0.26 | ) |   | $ | (0.34 | ) |
| Weighted-average      common shares outstanding,      basic and diluted                                                                                                                                                                                                                                                                                                                                                                                       |   |                                              | 22,474  |   |   |   | 22,474 |   |   |   | 22,494 |   |   |   | 26,468 |   |
| Product      related gross margin(1)                                                                      |   | $                                                 | 2,078   |   |   | $ | 1,616 |   |   | $ | 1,538 |   |   | $ | 1,914 |   |

----